WO2004087658A1 - Indolone-acetamide derivatives, processes for preparing them and their uses - Google Patents

Indolone-acetamide derivatives, processes for preparing them and their uses Download PDF

Info

Publication number
WO2004087658A1
WO2004087658A1 PCT/EP2004/002691 EP2004002691W WO2004087658A1 WO 2004087658 A1 WO2004087658 A1 WO 2004087658A1 EP 2004002691 W EP2004002691 W EP 2004002691W WO 2004087658 A1 WO2004087658 A1 WO 2004087658A1
Authority
WO
WIPO (PCT)
Prior art keywords
indol
oxo
hydrogen
dihydro
chloro
Prior art date
Application number
PCT/EP2004/002691
Other languages
French (fr)
Inventor
Jean-Philippe Starck
Benoît KENDA
Original Assignee
Ucb, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002520568A priority Critical patent/CA2520568A1/en
Application filed by Ucb, S.A. filed Critical Ucb, S.A.
Priority to MXPA05009089A priority patent/MXPA05009089A/en
Priority to DE602004029245T priority patent/DE602004029245D1/en
Priority to EP04720863A priority patent/EP1620399B1/en
Priority to JP2006504696A priority patent/JP2006522041A/en
Priority to AT04720863T priority patent/ATE482193T1/en
Priority to AU2004226288A priority patent/AU2004226288A1/en
Priority to US10/550,667 priority patent/US7645887B2/en
Priority to BRPI0408863-8A priority patent/BRPI0408863A/en
Publication of WO2004087658A1 publication Critical patent/WO2004087658A1/en
Priority to NO20055026A priority patent/NO20055026L/en
Priority to HK06110230A priority patent/HK1089768A1/en
Priority to US12/622,533 priority patent/US7964593B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2

Definitions

  • the present invention concerns indolone-acetamlde derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals .
  • European Patent No. 0 162 036 Bl discloses the compound (S)- ⁇ -ethyl-2-oxo-l-pyrrolidine acetamide, which is known under the International Nonproprietary Name of levetiracetam.
  • Levetiracetam a laevorotatory compound, is disclosed as a protective agent for the treatment and prevention of hypoxic and ischemic type aggressions of the central nervous system.
  • This compound is also effective in the treatment of epilepsy, a therapeutic indication for which it has been demonstrated that its dextrorotatory enantiomer (R)- ⁇ -ethyl-2-oxo-l-pyrrolidine acetamide, also known from European Patent No. 0 165 919 Bl, completely lacks activity (A.J. GOWER et al, Eur. J. Pharmacol., 222, (1992), 193-203).
  • Russian patent application SU 841264 discloses 2-(2-oxo-2,3-dihydro-lH- indol-l-yl)acetamide and its anticonvulsant activity.
  • the invention therefore provides a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
  • R! is hydrogen
  • R- 2 is hydrogen or Cl-20-alkyl
  • R3 IS hydrogen, CI-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W- ⁇ i ⁇ ,
  • R ⁇ a is hydrogen, Cl-20-alkyl or a group of formula:
  • NR ⁇ R ⁇ a is a group of formula
  • R 4 is hydrogen
  • R ⁇ is hydrogen; nitro; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-aIkyl; -S ⁇ 2-Cl-4-alkyl; -SONH2; Cl-20-alkyl unsubstituted or substituted by halogen; or
  • R 6 is hydrogen, Cl-20-alkyl or halogen
  • R 7 is hydrogen, Cl-20-alkyl or halogen
  • R8 is aryl or heterocycle
  • R9, R*0, R ⁇ a and R* l are independently selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R 10 and R 10a together form a C3-6-alkylene,
  • Rl2 i hydrogen, Cl-4-alkyl, halogen or hydroxy
  • Rl4 is aryl, heterocycle or a group of formula -V-R- ⁇ V is Cl-12-aTkylene,
  • Rl° is aryl or heterocycle
  • m is 1 to 4
  • n is 0 or 1
  • at least one of R ⁇ , R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen
  • R 3 is H or 2,6-diisopropylphenyl
  • R 3a is H.
  • the invention provides a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
  • R! is hydrogen
  • R 2 is hydrogen or Cl-20-alkyl
  • R3 is hydrogen, Cl-20-aIkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°,
  • R 3a S h dro en, Cl-20-alkyl or a group of formula:
  • NR 3 R3 is a group of formula
  • R 4 is hydrogen
  • R5 is hydrogen; nitro; halogen; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen,
  • R6 is hydrogen, Cl-20-alkyl or halogen
  • R 7 is hydrogen, Cl-20-alkyl or halogen
  • R8 is aryl or heterocycle
  • R9, RIO, RlO a and RU are independently selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R 10 and R 10a together form a C3-6-alkylene,
  • R 2 is hydrogen, Cl-4-alkyl, halogen or hydroxy
  • Rl3 is hydrogen, or CR* 2 R1 3 is dioxolanyl,
  • R ⁇ 4 is aryl, heterocycle or a group of formula -V-R- ⁇ V is Cl-12-alkylene
  • R.15 is aryl or heterocycle, m is 1 to 4, n is 0 or 1 , and at least one of R ⁇ , R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen, R 3 is H or 2,6-d ⁇ sopropylphenyl, and R 3a is H.
  • alkyl as used herein, is defined as including saturated, monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof and containing 1-20 carbon atoms, preferably 1-6 carbon atoms and more preferably 1-4 carbon atoms for non-cyclic alkyl and 3-8 carbon atoms for cycloalkyl.
  • Alkyl moieties may optionally be substituted by 1 to 5 substituents independently selected from halogen, hydroxy, alkoxy, alkoxycarbonyl, ester or alkylamino.
  • Preferred alkyl groups are methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, n-butyl, 2- fluoroethyl, 3-hydroxypropyl, 3-hydroxy-2,2-dimethylpropyl, l-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3-ethoxypropyl, 2-ethoxy-2-oxoethyl and 3- (d ⁇ nethyla ⁇ nino)propyl.
  • cycloalkyl refers to a monovalent group of 3 to 18 carbon atoms, preferably 4-8 carbon atoms, derived from a saturated cyclic or polycyclic hydrocarbon which may be substituted by any suitable group including but not limited to one or more moieties selected from groups as described above for the alkyl groups.
  • Preferred cycloalkyl group is cycloheptyl.
  • alkylene represents a divalent alkyl group, having straight or branched moieties, containing 1-12 carbon atoms, preferably 1-6 carbon atoms, and being optionally substituted with any suitable group, including but not limited to one or more moieties selected from groups as described above for the alkyl groups.
  • Preferred alkylene groups are methylene, ethylene, hydroxyethylene, trimethylene or propylene.
  • cycloalkenyl is defined as a cyclic unsaturated hydrocarbon radical having at least one double bond, containing 4-20 carbon atoms, preferably 5-8 carbon atoms, and being optionally substituted with any suitable group, including but not limited to one or more moieties selected from groups as described above for the alkyl groups.
  • Preferred cycloalkenyl group is 6- (hydroxymethyl)cyclohex-3-en-l-yl.
  • aryl is defined as including an organic radical derived from an aromatic hydrocarbon consisting of 1-3 rings and containing 6-30 carbon atoms by removal of one hydrogen, such as phenyl and naphthyl each optionally substituted by 1 to 5 substituents independently selected from halogen, hydroxy, nitro, Cl-6-alkyl, Cl-6-alkoxy, Cl-6-alkylsulfonyl, trifluoromethylthio or pyridinylalkyl.
  • Aryl radicals are preferably phenyl radicals.
  • Preferred aryl groups are phenyl, 3-hydroxyphenyl, 3-fluorophenyl, 3-methylphenyl, 4-methylphenyl, 4- hydroxyphenyl, 4-hydroxy-3-methoxyphenyl, 3-(2-pyridin-2-ylethyl)phenyl, 3,4- dimethylphenyl, 4-tert-butylphenyl, 4-methylsulfonylphenyl, 2-nitrophenyl, 2-chloro- 6-fluorophenyl, 2-[(trifluoromethyl)thio]phenyl, 2-chlorophenyl or 4-bromophenyl.
  • halogen as used herein, includes an atom of CI, Br, F, I.
  • nitro represents a group of the formula -NO2.
  • hydroxy represents a group of the formula -OH.
  • alkoxy represents a group of formula -OR" wherein R° is an alkyl group, as defined above.
  • esters represents a group of formula -COOR c wherein R c is an alkyl group or an aryl group, as defined above.
  • alkoxycarbonyl represents a group of formula - COOR° wherein R° is an alkyl group, as defined above.
  • amino represents a group of the formula -NH2-
  • alkylamino represents a group of formula -NHR e or -NR e Rf wherein R e and R ⁇ are alkyl group as defined above.
  • alkylsulfonyl as used herein is defined as representing a group of formula -SO2-RS. wherein R ⁇ is Cl-4-alkyl.
  • heterocycle as used herein is defined as including an aromatic or non aromatic cycloalkyl or cycloalkenyl moiety as defined above, having at least one O, S and/or N atom mterrupting the carbocyclic ring structure and optionally, one of the carbon of the carbocyclic ring structure may be replaced by a carbonyl.
  • Nbn-timiting examples of aromatic heterocycles are pyrazol l, furyl, imidazolyl, triazolyl, oxazolyl, pyridinyl, pyrrolyl, thienyl, isothiazolyl, benzimidazolyl, tetrazolyl, isooxazolyl, oxazolyl, thiazolyl, 1,2,4-thiadiazolyl, oxadiazole, pyridazinyl, pyrimidinyl, pyrazinyl, isoindolyl, triazolopyridfnyl, irnidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, quinazolinyl, quinolizinyl, naphthyridinyl, quinolyl, isoquinolyl, isobenzofuranyl, benzothienyl, indolyl,
  • Non-limiting examples of non aromatic heterocycles are tetrahydrofuranyl, piperidinyl, piperidyl, piperazinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, tiiiazolidinyl, indolinyl, tetrahydrobenzazocinyl, dihydroisochromenyl, tetrahydropyranyl, oxooctahydroquinolinyl, dioxolanyl, l-oxaspiro(4.5)dec-2-yl, pyrrolidinyl, 2-oxo-pyrrolidinyl, 8-thiabicyclo[3.2.1]cyclooctanyl, 1 ,4-dithiepanyl, tetrahydro-2H-thiopyranyl, azepanyl and azocanyl, optionally substituted by 1 to 5 substituents independently selected from
  • More preferred non aromatic heterocycles are tetrahydrofuranyl, piperidinyl, piperidyl, piperazfnyl, imidazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, thiazolidinyl, indolinyl, tetrahydro- 1-benzazocin- 1 (2H) ⁇ yl, 3,4-dihydro- lH-isochromen- 1 -yl, tetrahydropyranyl, oxooctahydroqulnolinyl and dioxolanyl.
  • heterocycle also includes bicyclic, tricyclic and tetracyclic, spiro groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cycloalkyl ring, a cycloalkenyl ring or another monocyclic heterocyclic ring or where a monocyclic heterocyclic group is bridged by an alkylene group, such as quinuclidinyl, 7-azabicyclo(2.2. l)heptanyl, 7-oxabicyclo(2.2. l)heptanyl and 8- azabicyclo (3.2.1) octanyl.
  • pyridinylalkyl represents a group of formula -R n - pyridinyl in which R n is Cl-4-alkylene.
  • R 2 is hydrogen or Cl-4-alkyl.
  • R 2 is hydrogen, methyl or ethyl. More preferably, R 2 is hydrogen or methyl.
  • R 3 is hydrogen; Cl-6-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl or alkylarnino;
  • R8 is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, Cl-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluorornethylthio; furyl unsubstituted or substituted by methyl; pyrazolyl; pyridinyl; morpholinyl; tetrahydrobenzazocinyl; piperidinyl unsubstituted or substituted by methyl; dihydroisochromenyl or dihydroimidazolyl.
  • R 3 is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3- hydroxypropyl, 3-hydroxy-2,2-dimethylpropyl, l-(hydroxymethyl)propyl, 3,3,3- tr ⁇ ffuoro-2-hydroxypro ⁇ yl, 3-ethoxypropyl, 2-ethoxy-2-oxoethyl, 3- (dimethylamino)propyl, 6-(hydroxymethyl)cyclohex-3-en-l-yl, 3-hydroxyphenyl, 3- fluorophenyl, 3-(2-pyridin-2-ylethyl)phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3-methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 2-chloro- 6-fluorobenzyl, 2-[(trifluoromethyl)thio]benzyl, 2-hydroxy
  • R 3a is hydrogen, methyl or tetrahydrofuran-2-ylmethyl. More preferably, R 3 is hydrogen.
  • NR 3 R 3a is piperidinyl unsubstituted or substituted by hydroxy; thiornorpholinyl; thiazolidinyl unsubstituted or substituted by Cl-4- alkoxycarbonyl; 2,5-dihydro-lH-pyrrol-l-yl; l,4-dioxa-8-azaspiro[4.5]dec-8-yl; 4- oxooctahydro-l(2H)-quinolinyl; or a group of formula
  • R ⁇ 4 is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, Cl-4-alkyl; or a group of formula -V-Rl° wherein V is unsubstituted Cl-4- alkylene and R*5 is phenyl or morpholinyl.
  • NR 3 R 3a is 4-pyridin-2-ylpiperazin-l-yl, 4-(3- methylphenyl)piperazin-l-yl, 4-(4-hydroxyphenyl)piperazin-l-yl, 4-(2- phenylethyl)piperazin-l-yl, 4-(2-morpholin-4-ylethyl)piperazin-l-yl, 3- hydroxypiperidin- 1 -yl, thiomorpholin-4-yl, 4-methoxycarbonyl- 1 , 3-thiazolidin-3-yl, 2,5-dihydro-lH-pyrrol-l-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl or 4-oxooctahydro- 1 (2H) -quinolinyl.
  • R ⁇ is hydrogen, nitro, halogen, Cl-4-alkyl, unsubstituted or substituted by halogen, or Cl-4-alkoxy unsubstituted or substituted by halogen.
  • RP is hydrogen, methyl, ethyl, trifluoromethyl, rrifluoromethoxy, n- propyl, isopropyl, nitro, or halogen. More preferably, R ⁇ is halogen or trifluoromethyl.
  • is hydrogen, Cl-6-alkyl or halogen.
  • R ⁇ is hydrogen, methyl or CI. More preferably, R ⁇ is hydrogen. Generally, R 7 is hydrogen, methyl or halogen.
  • R 7 is hydrogen, methyl, Br, F or CI. More preferably, R 7 is hydrogen, Br or F. Combinations of one or more of these preferred compound groups are especially preferred.
  • the invention provides a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
  • R! is hydrogen, R 2 is hydrogen or Cl-4-alkyl,
  • R 3 is hydrogen; Cl-6-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl or alkylamino; C5-7- c cloalkyl; (hydroxymethyl)cyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, Cl-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl, trifluorornethylthio or pyridinylalkyl; pyridinyl unsubstituted or substituted by methoxy; triazolyl; Cl-4-alkoxy; or a group of formula -W-R ⁇ , R 3a is hydrogen, Cl-4-alkyl or a group of formula
  • R 3a is piperidinyl unsubstituted or substituted by hydroxy; thiomorpholinyl; thiazolidinyl unsubstituted or substituted by Cl-4-alkoxycarbonyl; 2,5-dihydro-lH- pyrrol-1-yl; l,4-dioxa-8-azaspiro[4.5]dec-8-yl; 4-oxooctahydro-l(2H)-quinolinyl; or a group of formula
  • R 4 is hydrogen, R5 is hydrogen; nitro; halogen; Cl-4-alkyl, unsubstituted or substituted by halogen; or Cl-4-alkoxy unsubstituted or substituted by halogen,
  • R6 is hydrogen, Cl-6-alkyl or halogen
  • R 7 is hydrogen, methyl or halogen
  • R!4 is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, Cl-4-alkyl; or a group of formula -V-R- ⁇
  • V is unsubstituted Cl-4-alkylene
  • R!5 is phenyl or morpholinyl, m is 1 to 4, and at least one of R , R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen, R 3 is
  • R 3a is H.
  • the invention provides a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
  • R! is hydrogen
  • R 2 is hydrogen, methyl or ethyl
  • R 3 is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3-hydroxypropyl, 3-hydroxy-2,2- dimethylpropyl, l-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3- ethoxypropyl, 2-ethoxy-2-oxoethyl, 3-(dirnethylamino)propyl, 6- (hydroxymethyl)cyclohex-3-en-l-yl, 3-hydroxyphenyl, 3-fluorophenyl, 3-(2-pyridin-2- ylethyl)phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3- methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 2-chloro-6-fluorobenzyl, 2-
  • RP is hydrogen, methyl, ethyl, trifluoromethyl, trifluoromethoxy, n-propyl, isopropyl, nitro or halogen
  • R is hydrogen, methyl or CI
  • R 7 is hydrogen, methyl, Br, F or CI
  • at least one of RP, R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen
  • R 3 is H or 2,6-diisopropylphenyl
  • R 3a is H.
  • R 2 is hydrogen or methyl
  • R 3 is hydrogen
  • R 3a is hydrogen
  • RP is halogen or trifluoromethyl
  • R ⁇ is hydrogen
  • R 7 is hydrogen, Br or F.
  • R 2 is Cl-20-alkyl
  • the carbon atom to which R 2 is attached is preferably in the "S"-configuration.
  • Preferred compounds are: 2-(5-iodo-2-oxo-2,3-dihydro-lH-indol-l- yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-mdol-I-yl)acetamide; 2-(5,7-dibromo- 2-oxo-2, 3-dihydro- lH-indol- l-yl)acetamide; 2-(5-nitro-2-oxo-2,3-dihydro- lH-indol- 1 - yl)acetamide; 2-(5-methyl-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide; 2-(5-chloro-2- oxo-2,3-dihydro-lH-indol-l-yl)propanamide; (2R)-2-(5-chloro-2-ox
  • More preferred compounds are: 2-(5-iodo-2-oxo-2, 3-dihydro- lH-indol-1- yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide; 2-(5,7-dibromo- 2-oxo-2,3-dihydro- lH-indol- l-yl)acetamide; (2S)-2-(5-chloro-2-oxo-2,3-dihydro- 1H- indol-l-yl)propanamide; 2-[2-oxo-5-(trifluorornethyl)-2,3-dihydro-lH-indol-l- yl]acetarnide and 2-(5-cMoro-7-fluoro-2-oxo-2,3-dihydro-lH-indol-l-yl)ace
  • the invention relates to a compound selected from 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide and (2S)-2-(5-chloro-2- oxo-2,3-dihydro-'lH-indol-l-yl)propanamide.
  • the "pharmaceutically acceptable salts" according to the invention include therapeutically active, non-toxic base salt forms which the compounds of formula I are able to form.
  • the compounds of formula I containing acidic protons may be converted into their therapeutically active, non-toxic base addition salt forms, e.g. metal or amine salts, by treatment with appropriate organic and inorganic bases.
  • Appropriate base salt forms include, for example but not limited to, ammonium salts, alkali and earth alkaline metal salts, e.g. lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. N-methyl-D-glucarnine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • salt forms can be converted into the free forms by treatment with an appropriate acid.
  • Compounds of the formula I and their salts can be in the form of a solvate, which is included within the scope of the present invention.
  • solvates include for example hydrates, alcoholates and the like.
  • Many of the compounds of formula I and some of their intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem., 45 (1976) 11-30.
  • the invention also relates to all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds of formula I or mixtures thereof (including all possible mixtures of stereoisomers).
  • This reaction may be carried out using Raney nickel in an inert solvent, preferably THF, at a temperature comprised between 0 °C and 40 °C, or as described in: Mehta L., Parrick J., Payne F., J. Chem. Research (S) (1998), 190-191.
  • an inert solvent preferably THF
  • Compounds of formula II may be prepared by alkylation of a compound of formula III with a compound of formula IV according to the equation: wherein Hal is a halogen atom, preferably Br or CI, and R , R 2 , R 3 , R 3a , R4 ( R and R 7 have the same definitions as described above.
  • This reaction may be carried out with a strong base, for example sodium hydride, at a temperature comprised between 0 and 40 °C and in an inert solvent, for example DMF under an inert atmosphere, or as described in patent GB 1,309,692 (UCB).
  • a strong base for example sodium hydride
  • an inert solvent for example DMF under an inert atmosphere
  • R 4 , R ⁇ and R 7 have the same definitions as described above.
  • This reaction may be carried out at a temperature comprised between 25 and 100 °C in an inert solvent or in acetic acid, in the presence of a Lewis acid, preferably BF3-Et2 ⁇ under an inert atmosphere.
  • a Lewis acid preferably BF3-Et2 ⁇ under an inert atmosphere.
  • some compounds having the general formula I may be prepared by oxidative bromination of the corresponding indole of formula (VI) followed by the reduction of compound (VII) according to the equation:
  • Hal is an halogen atom, preferably Br or CI.
  • This reaction may be carried out in the presence of a strong base, preferably sodium hydride, at a temperature comprised between 0 and 40 °C, in an inert solvent, for example DMF, under an inert atmosphere, or as described in patent GB 1,309,692 (UCB).
  • a strong base preferably sodium hydride
  • R ⁇ is a hydrogen ⁇ with a N-halosuccinirnide according to the procedure described in: Castanet A.-S., Colobert F., Broutih P.-E., Tetrahedron Lett. (2002), 43,
  • some compounds having the general formula I may be prepared by nitration of the corresponding compound of formula I wherein is a hydrogen according to procedure described in: Sun L., Rubin J.R., Kraker A.J., Showalter H.D., J. Heterocyclic Chem. (1997), 34, 1399-1405.
  • some compounds having the general formula I may be prepared by coupling of an amine of formula NHR R 3a with a carboxylic acid derivative of formula IX in the presence of a coupling agent such as dicyclohexylcarbodiimide in dichloromethane or THF.
  • a coupling agent such as dicyclohexylcarbodiimide in dichloromethane or THF.
  • the present invention concerns also the synthesis intermediates of formula II or stereoisomeric forms thereof,
  • R! is hydrogen
  • R 2 is hydrogen or Cl-20-alkyl
  • R 3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°,
  • R 3a is hydrogen, Cl-20-alkyl or a group of formula:
  • NR 3 R 3a is a group of formula
  • R 4 is hydrogen
  • R ⁇ is hydrogen; nitro; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl;
  • R is hydrogen, Cl-20-alkyl or halogen
  • R 7 is hydrogen, Cl-20-alkyl or halogen
  • X is O, S or NH
  • R ⁇ is aryl or heterocycle
  • Rp, RIO, R11 gj-g independently selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R O and RlOa together form a C3-6-alkylene,
  • R ⁇ is hydrogen, Cl-4-alkyl, halogen or hydroxy
  • R 3 is hydrogen, or CR1 2 R1 is dioxolanyl
  • R!4 is aryl, heterocycle or a group of formula - -R- ⁇
  • V is Cl-12-alkylene
  • R ⁇ ° is aryl or heterocycle
  • m is 1 to 4
  • n is O or 1
  • at least one of R ⁇ , R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen
  • R 3 is
  • R 3a is H.
  • the present invention concerns also the synthesis intermediates of formula II or stereoisomeric forms thereof,
  • R! is hydrogen
  • R 2 is hydrogen or Cl-20-alkyl
  • R 3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°,
  • R a is hydrogen, Cl-20-alkyl or a group of formula:
  • NR 3 R 3a is a group of formula 7.
  • R 4 is hydrogen
  • R 5 is hydrogen; nitro; halogen; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen,
  • R 6 is hydrogen, Cl-20-alkyl or halogen
  • R 7 is hydrogen, Cl-20-alkyl or halogen
  • X is O, S or NH
  • R is aryl or heterocycle, , R!0 > RlOa and pll ⁇ Q independenlty selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or RIO a d RlOa together form a C3-6-alkylene,
  • Rl is hydrogen, Cl-4-alkyl, halogen or hydroxy
  • R* 3 is hydrogen, or CR* 2 R1 3 is dioxolanyl, R 4 is aryl, heterocycle or a group of formula -V-R ⁇ ,
  • V is Cl-12-alkylene
  • Rl° is aryl or heterocycle
  • m is 1 to 4
  • n is 0 or 1
  • at least one of R ⁇ , R6 or R 7 is different from hydrogen when R 2 is hydrogen
  • R 3 is
  • R 3a is H.
  • the synthesis intermediates of formula II are selected from the group consisting of: 2-(5'-methyl-2'-oxospiro[l,3-dithiolane-2,3'-indol]-l'(2'H)- yljacetamide; 2-[2'-oxo-5'-[(tr uoromethyl)oxy]spiro[l,3-dithiolane-2 ) 3 , -indol]-l , (2'H)- yl]aceta ⁇ mde; 2-[5'-(l-methylemyl)-2 , -oxospiro[l,3-di1 ⁇ iolane-2,3'-indol]-l'(2 ⁇ )- yljacetamide; 2-(5'-ethyl-2'-oxospfro[l,3-dithiolane-2,3'-indol]-l'(2 ⁇ )-yl)acetar ⁇ ide
  • the invention concerns also the synthesis intermediates of formula III or stereoisomeric forms thereof,
  • R 4 is hydrogen
  • R is hydrogen; nitro; azido; cyano, -S-Cl-4-alkyl; -SO-Cl-4-alkyl; -S ⁇ 2-Cl-4-alkyl; -SO H2; Cl-20-alkyl unsubstituted or substituted by halogen; or C 1-20-alkoxy unsubstituted or substituted by halogen, ⁇ is hydrogen, Cl-20-alkyl or halogen, R 7 is hydrogen, Cl-20-alkyl or halogen, and at least one of R , R ⁇ or R 7 is different from hydrogen.
  • the invention concerns also the synthesis intermediates of formula III or stereoisomeric forms thereof,
  • R 4 is hydrogen, ⁇ is hydrogen; nitro; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20- alkoxy unsubstituted or substituted by halogen,
  • R is hydrogen, Cl-20-alkyl or halogen
  • R 7 is hydrogen, Cl-20-alkyl or halogen, and at least one of R ⁇ , R ⁇ or R 7 is different from hydrogen.
  • the synthesis intermediates of formula III are selected from the group consisting of: 5'-methylspiro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one; 5'-
  • 2,3'-indol]-2'(l ⁇ )-one 5'-fluorospiro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one; 5',7'- dimethylspiro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one; 5'-propylspiro[l,3-dithiolane-2,3 , - indol]-2'(l'H)-one; 5'-(tr uoromethyl)spfro[l,3-dithiolane-2,3'-indol]-2 , (l ⁇ )-one; and
  • the present invention concerns also the synthesis intermediates of formula VI or stereoisomeric forms thereof,
  • R! is hydrogen
  • R 2 is hydrogen or Cl-20-alkyl
  • R 3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°,
  • R a is hydrogen, Cl-20-alkyl or a group of formula:
  • R or NR R a is a group of formula:
  • R 4 is hydrogen
  • R5 is hydrogen; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl;
  • R is hydrogen, Cl-20-alkyl or halogen
  • X is O, S or NH
  • R 9 , R 10 , R 10a and R 1 1 are independenlty selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R 10 and Rl°a together form a C3-6-alkylene,
  • R* is hydrogen, Cl-4-alkyl, halogen or hydroxy
  • R 3 is hydrogen, or CR ⁇ 2 R1 3 is dioxolanyl, Rl4 is aryl, heterocycle or a group of formula -V-R- ⁇
  • V is Cl-12-alkylene
  • R ⁇ 5 is aryl or heterocycle
  • m is 1 to 4
  • n is 0 or 1
  • at least one of R ⁇ , R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen, R 3 is
  • R a is H.
  • the present invention concerns the synthesis intermediates of formula VI or stereoisomeric forms thereof, wherein R! is hydrogen, R 2 is hydrogen or Cl-20-alkyl,
  • R 3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°
  • R a is hydrogen, Cl-20-alkyl or a group of formula:
  • R a is a group of formula:
  • R 4 is hydrogen
  • R ⁇ is hydrogen; halogen; or Cl-20-alkyl unsubstituted or substituted by halogen,
  • R6 is hydrogen, Cl-20-alkyl or halogen
  • R 7 is hydrogen, C2-20-alkyl or halogen
  • X is O, S or NH
  • R ⁇ is aryl or heterocycle
  • R ⁇ , R 10 , Rl° a and R 11 are independenlty selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R 10 and R 10a together form a C3-6-alkylene,
  • R 2 is hydrogen, Cl-4-alkyl, halogen or hydroxy
  • R* is hydrogen, or CR ⁇ R-*- is dioxolanyl
  • R-*- 4 is aryl, heterocycle or a group of formula -V-R- ⁇
  • V is Cl-12-alkylene
  • RIS is aiyl or heterocycle
  • m is 1 to 4
  • n is 0 or 1
  • at least one of R , R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen, R 3 is
  • R 3a is H.
  • the synthesis intermediates of formula VI are selected from the group consisting of : 2-(5-chloro-lH-indol-l-yl)propanamide;
  • the present invention concerns also the synthesis intermediates of formula DC or stereoisomeric forms thereof,
  • R! is hydrogen
  • R 2 is hydrogen or Cl-20-alkyl
  • R 4 is hydrogen, ⁇ is hydrogen; nitro; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl;
  • R ⁇ is hydrogen, Cl-20-alkyl or halogen
  • R 7 is hydrogen, Cl-20-alkyl or halogen, and at least one of R ⁇ , R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen, R 3 is
  • the present Invention concerns the synthesis intermediates of formula IX or stereoisomeric forms thereof,
  • R)- is hydrogen
  • R 2 is hydrogen or Cl-20-alkyl
  • R 4 is hydrogen
  • R5 is hydrogen; nitro; halogen; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen
  • R is hydrogen, Cl-20-alkyl or halogen
  • R 7 is hydrogen, Cl-20-alkyl or halogen, and at least one of R ⁇ , R ⁇ or R 7 is different from hydrogen when R 2 is hydrogen, R 3 is H or 2,6-diisopropylphenyl, and R 3a is H.
  • the synthesis intermediate of formula IX is (5-chloro-2-oxo-2,3- dihydro-lH-indol-l-yl)acetic acid.
  • the present invention also concerns the synthesis intermediates 2-(7-fluoro-2- oxo-2,3-dihydro-lH-indol-l-yl)acetamide and ethyl (5-chloro-2-oxo-2,3-dihydro-lH- indol- 1 -yl) acetate .
  • the compounds according to the invention are useful for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsions.
  • These compounds may also be used for the treatment of Parkinson's disease.
  • These compounds may also be used for the treatment of dyskinesia induced by dopamine replacement therapy, tardive dyskinesia induced by administration of neuroleptlc drugs or Huntington Chorea.
  • the compounds according to the invention may also be used for treating other neurological disorders including bipolar disorders, mania, depression, anxiety, attention deficit hyperactivity disorder (ADHD), migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythrnla, myotonia, ***e abuse, stroke, myoclonus, tremor, essential tremor, simple or complex tics, Tourette syndrome, restless leg syndrome and other movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitls.
  • ADHD attention deficit hyperactivity disorder
  • the present invention also concerns a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof as defined above for use as a medicament.
  • the present invention concerns also the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of neurological and other disorders such as mentioned above.
  • the present invention concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of epilepsy, Parkinson's disease, dyskinesia, rnigraine, bipolar disorders, chronic pain, neuropathic pain, or bronchial, asthmatic or allergic conditions.
  • the methods of the invention comprise administration to a mammal (preferably human) suffering from above mentioned conditions or disorders, of a compound according to the invention in an amount sufficient to alleviate or prevent the disorder or condition.
  • the compound is conveniently adrninistered in any suitable unit dosage form, including but not limited to one containing 3 to 3000 mg, preferably 25 to 500 mg of active ingredient per unit dosage form.
  • treatment includes curative treatment and prophylactic treatment.
  • curative is meant efficacy in treating a current symptomatic episode of a disorder or condition.
  • prophylactic is meant prevention of the occurrence or recurrence of a disorder or condition.
  • epileptic seizure refers to a chronic neurologic condition characterised by unprovoked, recurrent epileptic seizures.
  • An epileptic seizure is the manisfestation of an abnormal and excessive synchronised discharge of a set of cerebral neurons; its clrnlcal manifestations are sudden and transient.
  • epilepsy as used herein can also refer to a disorder of brain function characterised by the periodic occurrence of seizures. Seizures can be "nonepileptic" when evoked in a normal brain by conditions such as high fever or exposure to toxins or "epileptic” when evoked without evident provocation.
  • seizure refers to a transient alteration of behaviour due to the disordered, synchronous, and rhythmic firing of populations of brain neurones.
  • Parkinsonian symptoms relates to a syndrome characterized by slowness of movement (bradykinesia), rigidity and / or tremor. Parkinsonian symptoms are seen in a variety of conditions, most commonly in idiopathic Parkinsonlsm (i.e. Parkinson's Disease) but also following treatment of schizophrenia, exposure to toxins/drugs and head injury. It is widely appreciated that the primary pathology underlying Parkinson's disease is degeneration, in the brain, of the dopamlnergic projection from the substantia nigra to the striatum. This has led to the widespread use of dopamine-replacing agents (e.g.
  • L- DOPA L-3,4-dihydroxyphenylalanlne
  • dopamlne agonists as symptomatic treatments for Parkinson's disease and such treatments have been successful in increasing the quality of life of patients suffering from Parkinson's disease.
  • dopamine-replacement treatments do have limitations, especially following long-term treatment. Problems can include a wearing-off of the anti-parkinsonian efficacy of the treatment and the appearance of a range of side-effects which manifest as abnormal involuntary movements, such as dyskinesias.
  • the term "dyskinesia" is defined as the development in a subject of abnormal involuntary movements.
  • Dyskinesias are characterised by the development in a subject of abnormal involuntary movements.
  • One way in which dyskinesias may arise is as a side effect of dopamine replacement therapy for parklnsonism or other basal ganglia- related movement disorders.
  • migraine means a disorder characterised by recurrent attacks of headache that vary widely in intensity, frequency, and duration.
  • the attacks are commonly unilateral and are usually associated with anorexia, nausea, vomiting, phonophobia, and/or photophobia. In some cases they are preceded by, or associated with, neurological and mood disturbances.
  • Migraine headache may last from 4 hours to about 72 hours.
  • the International Headache Society (IHS, 1988) classifies migraine with aura (classical migraine) and migraine without aura (common migraine) as the major types of migraine.
  • Migraine with aura consists of a headache phase preceded by characteristic visual, sensory, speech, or motor symptoms. In the absence of such symptoms, the headache is called migraine without aura.
  • bipolar disorders refers to those disorders classified as Mood Disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TM), American Psychiatry Association, Washington, DC, 1994). Bipolar disorders are generally characterised by spontaneously triggered repeated (i.e. at least two) episodes in which the patient's hyperexcitability, activity and mood are significantly disturbed, this disturbance consisting on some occasions of an elevation of mood and increased energy and activity (mania or hypomania), and in other occasions a lowering of mood and decreased energy and activity (depression). Bipolar disorders are separated into four main categories in the DSM-IV (bipolar I disorder, bipolar II disorder, cyclotnymia, and bipolar disorders not otherwise specified).
  • manic episode refers to a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood with signs of pressured speech and psychomotor agitation.
  • hypermanla refers to a less extreme manic episode, with lower grade of severity.
  • major depressive episode refers to a period of at least 2 weeks during which there is either depressed mood or the loss of interest or pleasure in nearly all activities with signs of impaired concentration and psychomotor retardation.
  • mixed episode refers to a period of time (lasting at least 1 week) in which the criteria are met both for a manic episode and for a major depressive episode nearly every day.
  • chronic pain refers to the condition gradually being recognised as a disease process distinct from acute pain. Conventionally defined as pain that persists beyond the normal time of healing, pain can also be considered chronic at the point when the individual realises that the pain is going to be a persistent part of their lives for the foreseeable future. It is likely that a majority of chronic pain syndromes involves a neuropathic component, which is usually harder to treat than acute somatic pain.
  • neurode pain refers to pain due to a dysfunctional nervous system, sometimes occurring following injury to the central nervous system (central pain), but more often caused by damage to peripheral nerves (painful peripheral neuropathy). Neuropathic pain is most likely caused by neural hyperexcitatlon in partially damaged nerves.
  • neuropathic pain painful reactions appear in response to normally neutral stimuli (allodynia) or as exaggerated reactions to painful stimuli (hyperalgesia). Spontaneous pain, not provoked by external stimuli, also occurs in neuropathic pain, and is the most difficult form of pain to measure and treat.
  • Tics refers to common and often disabling neurological disorders. They are frequently associated with behaviour difficulties, including obsessive- compulsive disorder, attention deficit hyperactivity disorder and impulse control.
  • Tics are involuntary, sudden, rapid, repetitive, nonrhythrnic stereotype movements or vocalizations. Tics are manifested in a variety of forms, with different durations and degrees of complexity.
  • Simple motor tics are brief rapid movements that often involve only one muscle group.
  • Complex motor tics are abrupt movements that involve either a cluster of simple movements or a more coordinated sequence of movements.
  • Simple vocal tics include sounds such as grunting, barking, yelping, and thoat clearing.
  • Tremor refers to an involuntary, rhythmical, oscillatory movement of a body part.
  • Tremor can be phenomenologically defined as tremor at rest or associated with an action. Such an action can be postural (maintenance of a limb position), kinetic (movement-related), or intentional (at the end of a purposeful movement).
  • Etlologically, tremor most often occurs in Parkinson's disease (Parkinsonian rest tremor) and in essential tremor (postural and kinetic tremor), which consists of hereditary and age-related forms. Tremor may also occur in dystonia and in multiple sclerosis.
  • Tremor can also be an exaggerated form of normal physiological tremor.
  • tremor frequency is an important criterion to distinguish between various forms of tremor.
  • Essential tremor has the highest incidence of all tremors. As it is age-related, it can be expected to increase in aging populations.
  • tremor may be primarily based on a brainstem (inferior olivary nucleus) - cerebellar dysfunction, whereas Parkinsonian tremor probably originates from abnormal activity within the basal ganglia. Excessive synchronization and/or hyperexcitation in neuronal circuits may underlie tremor activity.
  • the activity of the compounds of formula I, or their pharmaceutically acceptable salts, as anticonvulsants can be determined in the audiogenic seizures model.
  • the objective of this test is to evaluate the anticonvulsant potential of a compound by means of audiogenic seizures induced in sound-susceptible mice, a genetic animal model with reflex seizures.
  • seizures are evoked without electrical or chemical stimulation and the seizure types are, at least in part, sirriilar n their clinical phenomenology to seizures occurring in man (L ⁇ scher W. & Schmidt D., Epilepsy Res. (1998), 2, p. 145-181;
  • compounds of formula I or their pharmaceutically acceptable salts may be employed at an effective daily dosage and adjOjinistered in the form of a pharmaceutical composition. Therefore, another embodiment of the present invention concerns a pharmaceutical composition comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable diluent or carrier.
  • one or more of the compounds of formula I or a pharmaceutically acceptable salt thereof is intimately admixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical compounding techniques known to the skilled practitioner.
  • Suitable diluents and carriers may take a wide variety of forms depending on the desired route of administration, e.g., oral, rectal, parenteral or intranasal.
  • Pharmaceutical compositions comprising compounds according to the invention can, for example, be adininistered orally or parenterally, i.e., intravenously, intramuscularly or subcutaneously, intrathecally, by inhalation or intranasally.
  • compositions suitable for oral administration can be solids or liquids and can, for example, be in the form of tablets, pills, dragees, gelatin capsules, solutions, syrups, chewing-gums and the like.
  • the active ingredient may be mixed with an inert diluent or a non- toxic pharmaceutically acceptable carrier such as starch or lactose.
  • these pharmaceutical compositions can also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatine, a disfntegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetener such as sucrose or saccharin, or colouring agents or a flavouring agent such as pepperinlnt or methyl salicylate.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatine, a disfntegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetener such as sucrose or saccharin, or colouring agents or a flavouring agent such as pepperinlnt or methyl salicylate
  • compositions which can release the active substance in a controlled manner are in conventional form such as aqueous or oily solutions or suspensions generally contained in ampoules, disposable syringes, glass or plastics vials or infusion containers.
  • these solutions or suspensions can optionally also contain a sterile diluent such as water for injection, a physiological saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulphite, chelating agents such as ethylene diamine-tetra-acetle acid, buffers such as acetates, citrates or phosphates and agents for adjusting the osmolarity, such as sodium chloride or dextrose.
  • a sterile diluent such as water for injection, a physiological saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulphite, chelating agents such as ethylene diamine-tetra-acetle acid, buffers such as acetates,
  • compositions for oral administration are prepared using methods which are routinely used by pharmacists.
  • the amount of active ingredient in the pharmaceutical compositions can fall within a wide range of concentrations and depends on a variety of factors such as the patient's sex, age, weight and medical condition, as well as on the method of admimstration.
  • the quantity of compound of formula I in compositions for oral administration is at least 0.5 % by weight and can be up to 80 % by weight with respect to the total weight of the composition.
  • the compounds of formula I or the pharmaceutically acceptable salts thereof can be administered alone or in combination with other pharmaceutically active ingredients.
  • additional compounds which can be cited for use in combination with the compounds according to the invention are antivirals, antispastlcs (e.g. baclofen), antiemetics, antimanic mood stabilizing agents, analgesics (e.g. aspirin, ibuprofen, paracetamol), narcotic analgesics, topical anesthetics, opioid analgesics, lithium salts, antidepressants (e.g. mlanserin, fluoxetine, trazodone), tricyclic antidepressants (e.g.
  • xnipramine desipramlne
  • anticonvulsants e.g. valproic acid, carbamazeplne, phenytoin
  • antipsychotics e.g. risperidone, haloperidol
  • neuroleptics e.g. benzodiazepines (e.g. diazepam, clonazepam), phenothiazines (e.g.
  • Examples of compounds inducing neural inhibition mediated by GABA ⁇ receptors include the following: benzodiazepines, barbiturates, steroids, and anticonvulsants such as valproate, viagabatrine, tiagabine or pharmaceutical acceptable salts thereof.
  • Benzodiazepines include the 1,4-benzodiazepines, such as diazepam and clonazepam, and the 1,5-benzodiazepines, such as clobazam.
  • Preferred compound is clonazepam.
  • Barbiturates include phenobarbital and pentobarbital.
  • Preferred compound is phenobarbital.
  • Steroids include adrenocortlcotropic hormones such as tetracosactide acetate, etc.
  • Anticonvulsants include hydantoins (phenytoin, ethotoin, etc), oxazolidines
  • Preferred compounds include valproic acid, valpromide, valproate pivoxil, sodium valproate, semi-sodium valproate, divalproex, clonazepam, phenobarbital, vigabatrine, tiagabine and amantadine.
  • the compounds of formula I exhibit a potentiating effect on the compounds modulating neurotransrnission mediated by glutamate receptors enabling, in many cases, effective treatment of conditions and disorders under reduced risk of adverse effects.
  • Examples of compounds modulating neurotransrnission mediated by glutamate receptors include the following: NBQX and MK-801 or pharmaceutical acceptable salts thereof.
  • the daily dosage is in the range 3 to 3000 rrtilligra s (mg) of compounds of formula I.
  • the quantity of compound of formula I present is at least 0.5 % by weight and can be up to 33 % by weight with respect to the total weight of the composition.
  • the dosage unit is in the range 3 mg to 3000 mg of compounds of formula I.
  • the daily dose can fall within a wide range of dosage units of compound of formula I and is generally in the range 3 to 3000 mg. However, it should be understood that the specific doses can be adapted to particular cases depending on the individual requirements, at the physician's discretion.
  • the LBS binding compounds provided by this invention and labelled derivatives thereof may be useful as standards and reagents in detexn irilng the ability of tested compounds (e.g., a potential pharmaceutical) to bind to the LBS receptor.
  • Labelled derivatives of LBS ligands provided by this invention may also be useful as radiotracers for positron emission tomography (PET) imaging or for single photon emission computerized tomography (SPECT).
  • PET positron emission tomography
  • SPECT single photon emission computerized tomography
  • NMR spectra are recorded on a BRUKER AC 250 Fourier Transform NMR Spectrometer fitted with an Aspect 3000 computer and a 5mm dual probehead or BRUKER DRX 400 FT NMR fitted with a SG Indigo 2 computer and a 5 mm inverse geometry ⁇ -K/ ⁇ C/ ⁇ N triple probehead.
  • the compound is studied in DMSO-dg .(or CDCI3) solution at a probe temperature of 313 K or 300 K and at a concentration of 20 mg/ml.
  • the instrument is locked on the deuterium signal of DMSO-dg (or CDCI3). Chemical shifts are given in ppm downfield from TMS taken as internal standard. HPLC analyses are performed using one of the following systems:
  • Analyses are performed using a WATERS Alliance HPLC system mounted with an INERTSIL ODS 3, DP 5 ⁇ m, 250 X 4.6 mm column.
  • the gradient runs from 100 % solvent A (acetonitrile, water, TFA (10/90/0.1, v/v/v)) to 100 % solvent B (acetonitrile, water, TFA (90/10/0.1, v/v/v)) in 7 min with a hold at 100 % B of 4 min.
  • the flow rate is set at 2.5 ml/min and a split of 1/25 is used just before API source.
  • API spectra (+ or -) are performed using a FINNIGAN (San Jose, CA, USA) LCQ ion trap mass spectrometer.
  • APCI source operates at 450 °C and the capillary heater at 160 °C.
  • ESI source operates at 3.5 kV and the capillary heater at 210 °C.
  • Mass spectrometric measurements In DIP/EI mode are performed as follows: samples are vaporized by heating the probe from 50 °C to 250 °C in 5 min. El
  • Electrode Impact spectra are recorded using a FINNIGAN (San Jose, CA, USA) TSQ 700 tandem quadrupole mass spectrometer.
  • the source temperature is set at 150 °C.
  • Mass spectrometric measurements on a TSQ 700 tandem quadrupole mass spectrometer (Finnigan MAT, San Jose, CA, USA) in GC/MS mode are performed with a gas chromatograph model 3400 (Varian, Walnut Creek, CA, USA) fitted with a split/ splitless injector and a DB-5MS fused-silica column (15 m x 0.25 mm I.D., 1 ⁇ m) from J&W Scientific (Folsom, CA, USA). Helium (purity 99.999 %) is used as carrier gas.
  • the injector (CTC A200S autosampler) and the transfer line operate at 290 and 250 °C, respectively. Sample (1 ⁇ l) is injected in splitless mode and the oven temperature is programmed as follows: 50 °C for 5 min., increasing to 280 °C
  • the TSQ 700 spectrometer operates in electron impact (El) or chemical ionization (CI/CH4) mode (mass range 33 - 800, scan time 1.00 sec).
  • the source temperature is set at 150 °C.
  • Melting points are determined on a B ⁇ chi 535 or 545 Tottoli-type fusionometre, and are not corrected, or by the onset temperature on a Perkin Elmer DSC 7.
  • Preparative chromatographic separations are performed on silicagel 60 Merck, particle size 15-40 ⁇ m, reference 1.15111.9025, using Novasep axial compression columns (80 mm i.d.), flow rates between 70 and 150 ml/min. Amount of silicagel and solvent mixtures as described in individual procedures.
  • Preparative Chiral Chromatographic separations are performed on a DAICEL Chiralpak AD 20 ⁇ m, 100*500 mm column using an in-house build instrument with various rnixtures of lower alcohols and C5 to C8 linear, branched or cyclic alkanes at ⁇ 350 ml/min. Solvent mixtures as described in Individual procedures. The following abbreviations are used In the examples:
  • the stereochemical information is contained in the two columns headed "configuration".
  • the second column indicates whether a compound has no stereogenic center (achiral), is a pure enantiomer (pure), a racemate (rac) or is a mixture of two stereoisomers, possibly in unequal proportions (MIXT).
  • the first column contains the stereochemlcal assignment for the recognised center, following the IUPAC numbering used in the "IUPAC name" column. A number alone indicates the existence of both configurations at that center.
  • a number followed by 'R' or 'S' indicates the known absolute configuration at that center.
  • a number followed by ' ⁇ ' indicates the existence of only one but unknown absolute configuration at that center.
  • the letter (A, B) in front is a way of distinguishing the various enantiomers of the same structure.
  • Oxindole 1 (1 g, 5.25 rrrmol) was dissolved in CH3CN (20 ml). After addition of the NIS (1.3 g, 5.78 mmol), the TFA (217 ⁇ l, 1.57 mmol) was added and the reaction was allowed at room temperature for 16 h. After evaporation of the solvent, the rnixture was triturated in a 10 % aqueous solution of Na2S ⁇ 3. The beige solid formed was filtered, washed with water and with ether.
  • Oxindole 1 (1.77 g, 9.3 mmol) was dissolved in 90 % H2SO (6 ml) at room temperature, and NCS (1.24 g, 9.3 mmol) was slowly added with stirring. After 2 hours, the rnixture was poured into cold water. The precipitate was collected, washed several times with water and then with Et2 ⁇ . After cristallization from EtOH, 2-(5- chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide 3 was obtained as a white solid. Yield: 479 mg (23 %). MS (LC-MS, MH+): 225/227.
  • Example 5 Synthesis of 2-(5-met yl-2-oxo-2,3-dihydro-lH-indol-l-yl)acetarnide 24.
  • the Raney Nickel was prepared as an aqueous slurry after removing four fifth of water of the commercial solution.
  • Aqueous Raney nickel (10 ml) was added to a solution of compound 15 (4.06 g, 13.8 mmol) in 40 ml of distilled THF and the mixture was further vigourously stirred at room temperature. When no starting material was detected by thin layer chromatography, the mixture was diluted with THF and filtered through a Celite pad.
  • Example 6 Synthesis of 2-(5-cMoro-2-oxo-2,3-d ydro-lH-indol-l-yl)propanamide 32, 33 and 34.
  • Zinc dust (23.71 g, 0.58 mol) was added to a stirred solution of compound 31 (theorical: 58.4 mmol) in AcOH (110 ml) at 0 °C. After 1 hour, the reaction mixture was filtered through a Celite pad. The filtrate was diluted with AcOEt and cold water. The pH was adjusted to 7 and the layers were separated. The aqueous phase was extracted again with AcOEt. Organic layers were dried over Na2S ⁇ 4 and concentrated. The beige solid was cristallized in AcOEt and afforded 2-(5-chloro-2-oxo-2,3-dihydro- lH-indol-1 -yUpropanamide 32 as a white solid. Yield: 2.5 g (18 %).
  • ester 58 was obtained from 5-chloroindole and ethyl bromoacetate (instead of bromo-acetamide) using the methodology described in example 6.
  • the synthesis intermediate 2-(7-fluoro-2-oxo-2, 3-dihydro- lH-indol-1- yUacetamide may also be prepared according to one of the previous methods.
  • Example 8 LBS Binding Assay.
  • the inhibition constant (Kt) of a compound is determined in competitive binding experiments by measuring the binding of a single concentration of a radioactive ligand at equilibrium with various concentrations of the unlabeled test substance.
  • the concentration of the test substance inhibiting 50 % of the specific binding of the radioligand is called the IC50.
  • the equilibrium dissociation constant K j is proportional to the IC5 Q and is calculated using the equation of Cheng and Prusoff (Cheng Y. et al., Biochem. Pharmacol. (1972), 22, 3099-3108).
  • the concentration range usually encompasses 6 log units with variable steps (0.3 to 0.5 log). Assays are performed in mono- or duplicate, each Ki determination is performed on two different samples of test substance.
  • Cerebral cortex from 200-250 g male Sprague-Dawley rats are homogenised using a Potter S homogeniser (10 strokes at 1,000 rpm; Braun, Germany) in 20 mmol/1 Tris-HCl (pH 7.4), 250 rnmol/1 sucrose (buffer A); all operations are performed at 4 °C.
  • the homogenate is centrifuged at 30,000xg for 15 min.
  • the crude membrane pellet obtained is resuspended in 50 mmol/1 Tris-HCl (pH 7.4), (buffer B) and incubated 15 rnln at 37 °C, centrifuged at 30,000xg for 15 min and washed twice with the same buffer.
  • the final pellet is resuspended in buffer A at a protein concentration ranging from 15 to 25 mg/ml and stored in liquid nitrogen.
  • Membranes (150-200 ⁇ g of protein / assay) are incubated at 4 °C for 120 min in 0.5 ml of a 50 mmol/1 Tris-HCl buffer (pH 7.4) containing 2 mmol/1 MgCl 2 , 10 ⁇ 9 to 2.10 ⁇ 9 mol/1 of [ 3 H]-2-[4-(3-azidophenyl)-2-oxo- l-pyrrolidinyl]butanamlde and increasing concentrations of the test substance.
  • the non specific binding (NSB) is defined as the residual binding observed in the presence of a concentration of reference substance (e.g. 10 "3 mol/1 levetiracetam) that binds essentially all the receptors.
  • Membrane-bound and free radioligands are separated by rapid filtration through glass fiber filters (equivalent to Whatman GF/C or GF/B; VEL, Belgium) pre- soaked in 0.1 % polyethyleneirnine and 10 "3 mol/1 levetiracetam to reduce non specific binding.
  • Samples and filters are rinsed by at least 6 ml of 50 mmol/1 Tris-HCl (pH 7.4) buffer. The entire filtration procedure does not exceed 10 seconds per sample.
  • the radioactivity trapped onto the filters is counted by liquid scintillation in a ⁇ - counter (Tri-Carb 1900 or TopCount 9206, Camberra Packard, Belgium, or any other equivalent counter).
  • Data analysis is performed by a computerized non linear curve fitting method using a set of equations describing several binding models assuming populations of independent non-interacting receptors, which obey to the law of mass.
  • Example 9 Ariimal model of sound-susceptible mice.
  • the aim of this test is to evaluate the anticonvulsant potency of a compound in sound-susceptible mice, a genetic animal model with reflex seizures.
  • seizures are evoked without electrical or chemical stimulation and the seizure types are, at least in part, similar in their clinical phenomenology to seizures occurring in man (L ⁇ scher W. & Schmidt D., Epilepsy Res. (1998), 2, 145-181; Buchhalter J.R., Epilepsia (1993), 34, S31-S41).
  • the experimental design consists of several groups, one group receiving the vehicle control and the other groups different doses of the test-compound.
  • the compounds are adrrrlnlstered intraperitoneally 60 rninutes before the induction of audiogenic seizures.
  • the range of the doses adrnirtistered has a logarithmic progression, generally between 1.0 x 10 " ⁇ mol/kg and 1.0 x 10- mol/kg, but lower or higher doses are tested if necessary.
  • mice For testing, the animals are placed in small cages, one mouse per cage, in a sound-attenuated chamber. After a period of orientation of 30 seconds, the acoustic stimulus (90 dB, 10-20 kHz) is delivered for 30 seconds via loudspeakers positioned above each cage. During this interval, the mice are observed and the presence of the 3 phases of the seizure activity namely wild running, clonic and tonic convulsions, is recorded. The proportion of mice protected against wild running, clonic and tonic convulsions, respectively, is calculated. For active compounds, an ED50 value, i.e.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion.

Description

INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES
The present invention concerns indolone-acetamlde derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals .
European Patent No. 0 162 036 Bl discloses the compound (S)-α-ethyl-2-oxo-l-pyrrolidine acetamide, which is known under the International Nonproprietary Name of levetiracetam.
Levetiracetam, a laevorotatory compound, is disclosed as a protective agent for the treatment and prevention of hypoxic and ischemic type aggressions of the central nervous system. This compound is also effective in the treatment of epilepsy, a therapeutic indication for which it has been demonstrated that its dextrorotatory enantiomer (R)-α-ethyl-2-oxo-l-pyrrolidine acetamide, also known from European Patent No. 0 165 919 Bl, completely lacks activity (A.J. GOWER et al, Eur. J. Pharmacol., 222, (1992), 193-203).
Russian patent application SU 841264 discloses 2-(2-oxo-2,3-dihydro-lH- indol-l-yl)acetamide and its anticonvulsant activity.
It has now surprisingly been found that certain indolone-acetarnide derivatives demonstrate markedly improved therapeutic properties.
In one aspect the invention therefore provides a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
Figure imgf000002_0001
wherein
R! is hydrogen,
R-2 is hydrogen or Cl-20-alkyl,
R3 IS hydrogen, CI-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-Εiβ,
R^a is hydrogen, Cl-20-alkyl or a group of formula:
Figure imgf000002_0002
or NR^R^a is a group of formula
Figure imgf000003_0001
R4 is hydrogen,
R^ is hydrogen; nitro; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-aIkyl; -Sθ2-Cl-4-alkyl; -SONH2; Cl-20-alkyl unsubstituted or substituted by halogen; or
Cl-20-alkoxy unsubstituted or substituted by halogen,
R6 is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, Cl-20-alkyl or halogen,
W is Cl-12-alkylene, -NH- or -NHC(=0)-, X is O, S or NH,
Y is O, S, -CR1 R13-, -NR14- or -C(=0)-,
R8 is aryl or heterocycle,
R9, R*0, R^a and R* l are independently selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R10 and R10a together form a C3-6-alkylene,
Rl2 iS hydrogen, Cl-4-alkyl, halogen or hydroxy,
Rl3 iS hydrogen, or CR12R1 is dioxolanyl,
Rl4 is aryl, heterocycle or a group of formula -V-R-Α V is Cl-12-aTkylene,
Rl° is aryl or heterocycle, m is 1 to 4, n is 0 or 1, and at least one of R^, R^ or R7 is different from hydrogen when R2 is hydrogen, R3 is H or 2,6-diisopropylphenyl, and R3a is H.
In another aspect the invention provides a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
Figure imgf000003_0002
wherein R! is hydrogen,
R2 is hydrogen or Cl-20-alkyl,
R3 is hydrogen, Cl-20-aIkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°,
R3a S h dro en, Cl-20-alkyl or a group of formula:
Figure imgf000004_0001
or NR3R3 is a group of formula
Figure imgf000004_0002
R4 is hydrogen, R5 is hydrogen; nitro; halogen; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen,
R6 is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, Cl-20-alkyl or halogen,
W is Cl-12-alkylene, -NH- or -NHC(=0)-, X is O, S or NH,
Y is O, S, -CR12R13-, -NR14- or -C(=0)-,
R8 is aryl or heterocycle,
R9, RIO, RlOa and RU are independently selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R10 and R10a together form a C3-6-alkylene,
R 2 is hydrogen, Cl-4-alkyl, halogen or hydroxy,
Rl3 is hydrogen, or CR*2R13 is dioxolanyl,
R^4 is aryl, heterocycle or a group of formula -V-R-Α V is Cl-12-alkylene,
R.15 is aryl or heterocycle, m is 1 to 4, n is 0 or 1 , and at least one of R^, R^ or R7 is different from hydrogen when R2 is hydrogen, R3 is H or 2,6-dϋsopropylphenyl, and R3a is H. The term "alkyl", as used herein, is defined as including saturated, monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof and containing 1-20 carbon atoms, preferably 1-6 carbon atoms and more preferably 1-4 carbon atoms for non-cyclic alkyl and 3-8 carbon atoms for cycloalkyl. Alkyl moieties may optionally be substituted by 1 to 5 substituents independently selected from halogen, hydroxy, alkoxy, alkoxycarbonyl, ester or alkylamino. Preferred alkyl groups are methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, n-butyl, 2- fluoroethyl, 3-hydroxypropyl, 3-hydroxy-2,2-dimethylpropyl, l-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3-ethoxypropyl, 2-ethoxy-2-oxoethyl and 3- (dύnethylaιnino)propyl.
The term "cycloalkyl", as used herein, refers to a monovalent group of 3 to 18 carbon atoms, preferably 4-8 carbon atoms, derived from a saturated cyclic or polycyclic hydrocarbon which may be substituted by any suitable group including but not limited to one or more moieties selected from groups as described above for the alkyl groups. Preferred cycloalkyl group is cycloheptyl.
The term "alkylene", as used herein, represents a divalent alkyl group, having straight or branched moieties, containing 1-12 carbon atoms, preferably 1-6 carbon atoms, and being optionally substituted with any suitable group, including but not limited to one or more moieties selected from groups as described above for the alkyl groups. Preferred alkylene groups are methylene, ethylene, hydroxyethylene, trimethylene or propylene.
The term "cycloalkenyl", as used herein, is defined as a cyclic unsaturated hydrocarbon radical having at least one double bond, containing 4-20 carbon atoms, preferably 5-8 carbon atoms, and being optionally substituted with any suitable group, including but not limited to one or more moieties selected from groups as described above for the alkyl groups. Preferred cycloalkenyl group is 6- (hydroxymethyl)cyclohex-3-en-l-yl.
The term "aryl", as used herein, is defined as including an organic radical derived from an aromatic hydrocarbon consisting of 1-3 rings and containing 6-30 carbon atoms by removal of one hydrogen, such as phenyl and naphthyl each optionally substituted by 1 to 5 substituents independently selected from halogen, hydroxy, nitro, Cl-6-alkyl, Cl-6-alkoxy, Cl-6-alkylsulfonyl, trifluoromethylthio or pyridinylalkyl. Aryl radicals are preferably phenyl radicals. Preferred aryl groups are phenyl, 3-hydroxyphenyl, 3-fluorophenyl, 3-methylphenyl, 4-methylphenyl, 4- hydroxyphenyl, 4-hydroxy-3-methoxyphenyl, 3-(2-pyridin-2-ylethyl)phenyl, 3,4- dimethylphenyl, 4-tert-butylphenyl, 4-methylsulfonylphenyl, 2-nitrophenyl, 2-chloro- 6-fluorophenyl, 2-[(trifluoromethyl)thio]phenyl, 2-chlorophenyl or 4-bromophenyl. The term "halogen", as used herein, includes an atom of CI, Br, F, I. The term "nitro", as used herein, represents a group of the formula -NO2.
The term "hydroxy", as used herein, represents a group of the formula -OH.
The term "alkoxy", as used herein, represents a group of formula -OR" wherein R° is an alkyl group, as defined above.
The term "ester", as used herein, represents a group of formula -COORc wherein Rc is an alkyl group or an aryl group, as defined above.
The term "alkoxycarbonyl", as used herein, represents a group of formula - COOR° wherein R° is an alkyl group, as defined above. The term "amino", as used herein, represents a group of the formula -NH2-
The term "alkylamino", as used herein, represents a group of formula -NHRe or -NReRf wherein Re and R^ are alkyl group as defined above.
The term alkylsulfonyl, as used herein is defined as representing a group of formula -SO2-RS. wherein R§ is Cl-4-alkyl. The term "heterocycle", as used herein is defined as including an aromatic or non aromatic cycloalkyl or cycloalkenyl moiety as defined above, having at least one O, S and/or N atom mterrupting the carbocyclic ring structure and optionally, one of the carbon of the carbocyclic ring structure may be replaced by a carbonyl.
Nbn-timiting examples of aromatic heterocycles are pyrazol l, furyl, imidazolyl, triazolyl, oxazolyl, pyridinyl, pyrrolyl, thienyl, isothiazolyl, benzimidazolyl, tetrazolyl, isooxazolyl, oxazolyl, thiazolyl, 1,2,4-thiadiazolyl, oxadiazole, pyridazinyl, pyrimidinyl, pyrazinyl, isoindolyl, triazolopyridfnyl, irnidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, quinazolinyl, quinolizinyl, naphthyridinyl, quinolyl, isoquinolyl, isobenzofuranyl, benzothienyl, indolyl, indolizinyl, purinyl, carbazolyl, thieno(2,3- b)furanyl, thianthrenyl, benzothiazolyl, benzoxazolyl, cinnolinyl, quinoxalinyl, phenothiazinyl, isochromanyl and xanthenyl, optionally substituted by 1 to 5 substituents independently selected from halogen, hydroxy, thiol, amino, nitro, cyano, azido, Cl-6-alkoxy, Cl-6-alkylthio, Cl-6-alkyl, Cl-6-haloalkyl, formyl or ester. More preferred aromatic heterocycles are pyrazolyl, furyl, imidazolyl, triazolyl, oxazolyl and pyridinyl.
Non-limiting examples of non aromatic heterocycles are tetrahydrofuranyl, piperidinyl, piperidyl, piperazinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, tiiiazolidinyl, indolinyl, tetrahydrobenzazocinyl, dihydroisochromenyl, tetrahydropyranyl, oxooctahydroquinolinyl, dioxolanyl, l-oxaspiro(4.5)dec-2-yl, pyrrolidinyl, 2-oxo-pyrrolidinyl, 8-thiabicyclo[3.2.1]cyclooctanyl, 1 ,4-dithiepanyl, tetrahydro-2H-thiopyranyl, azepanyl and azocanyl, optionally substituted by 1 to 5 substituents independently selected from halogen, hydroxy, thiol, amino, nitro, cyano, azido, Cl-6-alkoxy, Cl-6-alkylthio, Cl-6-alkyl, Cl-6-haloalkyl, for yl or ester. More preferred non aromatic heterocycles are tetrahydrofuranyl, piperidinyl, piperidyl, piperazfnyl, imidazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, thiazolidinyl, indolinyl, tetrahydro- 1-benzazocin- 1 (2H)~yl, 3,4-dihydro- lH-isochromen- 1 -yl, tetrahydropyranyl, oxooctahydroqulnolinyl and dioxolanyl. The term "heterocycle" also includes bicyclic, tricyclic and tetracyclic, spiro groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cycloalkyl ring, a cycloalkenyl ring or another monocyclic heterocyclic ring or where a monocyclic heterocyclic group is bridged by an alkylene group, such as quinuclidinyl, 7-azabicyclo(2.2. l)heptanyl, 7-oxabicyclo(2.2. l)heptanyl and 8- azabicyclo (3.2.1) octanyl.
The term "pyridinylalkyl", as used herein, represents a group of formula -Rn- pyridinyl in which Rn is Cl-4-alkylene.
The term "azido" as used herein, represents a group of the formula -N3. The term "cyano" as used herein, represents a group of the formula -CN.
Generally, R2 is hydrogen or Cl-4-alkyl.
Preferably, R2 is hydrogen, methyl or ethyl. More preferably, R2 is hydrogen or methyl.
Generally, R3 is hydrogen; Cl-6-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl or alkylarnino;
C5-7-cycloalkyl; (hydroxymethyl)cyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, Cl-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl, trifluorornethylthio or pyridinylalkyl; pyridinyl unsubstituted or substituted by methoxy; triazolyl; Cl-4-alkoxy; or a group of formula -W-R^ wherein: Generally, W is CI-4-alkylene unsubstituted or substituted by halogen, hydroxy, Cl-4-alkyl or alkoxy; -NH-; or -NHC(=0)-; and
R8 is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, Cl-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluorornethylthio; furyl unsubstituted or substituted by methyl; pyrazolyl; pyridinyl; morpholinyl; tetrahydrobenzazocinyl; piperidinyl unsubstituted or substituted by methyl; dihydroisochromenyl or dihydroimidazolyl.
Preferably, R3 is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3- hydroxypropyl, 3-hydroxy-2,2-dimethylpropyl, l-(hydroxymethyl)propyl, 3,3,3- trτffuoro-2-hydroxyproρyl, 3-ethoxypropyl, 2-ethoxy-2-oxoethyl, 3- (dimethylamino)propyl, 6-(hydroxymethyl)cyclohex-3-en-l-yl, 3-hydroxyphenyl, 3- fluorophenyl, 3-(2-pyridin-2-ylethyl)phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3-methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 2-chloro- 6-fluorobenzyl, 2-[(trifluoromethyl)thio]benzyl, 2-hydroxy-2-phenylethyl, 2-(3,4- dimethoxyphenyl)ethyl, 2-(2-chlorophenyl)ethyl, 2-(4-methylphenyl)ethyl, (4- bromophenyl) amino, pyridin-3-yl, 6-methoxypyridin-3-yl, 4H-l,2,4-triazol-3-yl, pyridin-4-ylmethyl, (5-methyl-2-fuιyl)methyl, 3-(lH-pyrazol-l-yl)propyl, 2-morpholin- 4-ylethyl, 2- ((3 , , 5 , 6-tetrahydro- 1 -benzazocin- 1 (2H) -yljpropyl, 2- (2-methylpiperidin- 1 - yl)ethyl, 3,4-dihydro-lH-isochromen-l-ylmethyl, methoxy, (4-pyridinylcarbonyl)amino or 4,5-dihydro-lH-jτmdazol-2-ylamino. More preferably, R3 is hydrogen. Generally, R3a is hydrogen, Cl-4-alkyl or a group of formula .0,
wherein m 'J is 1 to 4.
Preferably, R3a is hydrogen, methyl or tetrahydrofuran-2-ylmethyl. More preferably, R3 is hydrogen.
In another embodiment, NR3R3a is piperidinyl unsubstituted or substituted by hydroxy; thiornorpholinyl; thiazolidinyl unsubstituted or substituted by Cl-4- alkoxycarbonyl; 2,5-dihydro-lH-pyrrol-l-yl; l,4-dioxa-8-azaspiro[4.5]dec-8-yl; 4- oxooctahydro-l(2H)-quinolinyl; or a group of formula
— N ^\ N-R 14
wherein R^4 is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, Cl-4-alkyl; or a group of formula -V-Rl° wherein V is unsubstituted Cl-4- alkylene and R*5 is phenyl or morpholinyl.
In a preferred embodiment, NR3R3a is 4-pyridin-2-ylpiperazin-l-yl, 4-(3- methylphenyl)piperazin-l-yl, 4-(4-hydroxyphenyl)piperazin-l-yl, 4-(2- phenylethyl)piperazin-l-yl, 4-(2-morpholin-4-ylethyl)piperazin-l-yl, 3- hydroxypiperidin- 1 -yl, thiomorpholin-4-yl, 4-methoxycarbonyl- 1 , 3-thiazolidin-3-yl, 2,5-dihydro-lH-pyrrol-l-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl or 4-oxooctahydro- 1 (2H) -quinolinyl.
Generally, R^ is hydrogen, nitro, halogen, Cl-4-alkyl, unsubstituted or substituted by halogen, or Cl-4-alkoxy unsubstituted or substituted by halogen.
Preferably, RP is hydrogen, methyl, ethyl, trifluoromethyl, rrifluoromethoxy, n- propyl, isopropyl, nitro, or halogen. More preferably, R^ is halogen or trifluoromethyl. Generally, R® is hydrogen, Cl-6-alkyl or halogen.
Preferably, R^ is hydrogen, methyl or CI. More preferably, R^ is hydrogen. Generally, R7 is hydrogen, methyl or halogen.
Preferably, R7 is hydrogen, methyl, Br, F or CI. More preferably, R7 is hydrogen, Br or F. Combinations of one or more of these preferred compound groups are especially preferred.
In a preferred embodiment, the invention provides a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
Figure imgf000009_0001
wherein
R! is hydrogen, R2 is hydrogen or Cl-4-alkyl,
R3 is hydrogen; Cl-6-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl or alkylamino; C5-7- c cloalkyl; (hydroxymethyl)cyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, Cl-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl, trifluorornethylthio or pyridinylalkyl; pyridinyl unsubstituted or substituted by methoxy; triazolyl; Cl-4-alkoxy; or a group of formula -W-R^, R3a is hydrogen, Cl-4-alkyl or a group of formula
Figure imgf000009_0002
or NR3R3a is piperidinyl unsubstituted or substituted by hydroxy; thiomorpholinyl; thiazolidinyl unsubstituted or substituted by Cl-4-alkoxycarbonyl; 2,5-dihydro-lH- pyrrol-1-yl; l,4-dioxa-8-azaspiro[4.5]dec-8-yl; 4-oxooctahydro-l(2H)-quinolinyl; or a group of formula
' \ 14
-N N— R
R4 is hydrogen, R5 is hydrogen; nitro; halogen; Cl-4-alkyl, unsubstituted or substituted by halogen; or Cl-4-alkoxy unsubstituted or substituted by halogen,
R6 is hydrogen, Cl-6-alkyl or halogen,
R7 is hydrogen, methyl or halogen,
W is Cl-4-alkylene unsubstituted or substituted by halogen, hydroxy, Cl-4-alkyl or alkoxy; -NH-; or -NHC(=0)-, R8 is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, Cl-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluoromethylthio; furyl unsubstituted or substituted by methyl; pyrazolyl; pyridinyl; morpholinyl; tetrahydrobenzazocinyl; piperidinyl unsubstituted or substituted by methyl; dihydroisochromenyl or dihydroimidazolyl,
R!4 is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, Cl-4-alkyl; or a group of formula -V-R-Α
V is unsubstituted Cl-4-alkylene,
R!5 is phenyl or morpholinyl, m is 1 to 4, and at least one of R , Rβ or R7 is different from hydrogen when R2 is hydrogen, R3 is
H or 2,6-dϋsopropylphenyl, and R3a is H.
In a more preferred embodiment, the invention provides a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
Figure imgf000010_0001
wherein
R! is hydrogen,
R2 is hydrogen, methyl or ethyl, R3 is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3-hydroxypropyl, 3-hydroxy-2,2- dimethylpropyl, l-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3- ethoxypropyl, 2-ethoxy-2-oxoethyl, 3-(dirnethylamino)propyl, 6- (hydroxymethyl)cyclohex-3-en-l-yl, 3-hydroxyphenyl, 3-fluorophenyl, 3-(2-pyridin-2- ylethyl)phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3- methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 2-chloro-6-fluorobenzyl, 2-
[(trifluoromethyl)thio]benzyl, 2-hydroxy-2-phenylethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2-chlorophenyl)ethyl, 2-(4-methylphenyl)ethyl, (4-bromophenyl)amino, pyridin-3-yl, 6-methoxypyridin-3-yl, 4H-l,2,4-triazol-3-yl, pyridin-4-ylmethyl, (5-methyl-2- fuiyl)methyl, 3-(lH-pyrazol-l-yl)propyl, 2-morpholin-4-ylethyl, 2-((3,4,5,6-tetrahydro- l-benzazocin-l(2H)-yl)propyl, 2-(2-methylpiperidin-l-yl)ethyl, 3,4-dihydro-lH- isochromen-1-ylmethyl, methoxy, (4-pyridinylcarbonyl)aπιino or 4,5-dihydro-lH- jτnidazol-2-ylaιnino, R3a is hydrogen, methyl or tetrahydrofuran-2-ylmethyl, or NR3R a 4-pyridin-2-ylpiperazin-l-yl, 4-(3-methylρhenyl)piperazin-l-yl, 4-(4- hydroxyphenyl)piperazin-l-yl, 4-(2-phenylethyl)piperazin-l-yl, 4-(2-morpholin-4- ylethyl)piperazin-l-yl, 3-hydroxypiperidin-l-yl, thiomorpholin-4-yl, 4- rnethoxycarbonyl-l,3-thiazolidin-3-yl, 2,5-dihydro-lH-pyrrol-l-yl, l,4-dioxa-8- azaspiro[4.5]dec-8-yl or 4-oxooctahydro-l(2H)-quinolinyl, R4 is hydrogen,
RP is hydrogen, methyl, ethyl, trifluoromethyl, trifluoromethoxy, n-propyl, isopropyl, nitro or halogen, R is hydrogen, methyl or CI, R7 is hydrogen, methyl, Br, F or CI, and at least one of RP, Rβ or R7 is different from hydrogen when R2 is hydrogen, R3 is H or 2,6-diisopropylphenyl, and R3a is H.
More preferably, R2 is hydrogen or methyl, R3 is hydrogen, R3a is hydrogen, RP is halogen or trifluoromethyl, Rβ is hydrogen and R7 is hydrogen, Br or F. In all the above-mentioned scopes, when R2 is Cl-20-alkyl, the carbon atom to which R2 is attached is preferably in the "S"-configuration.
Preferred compounds are: 2-(5-iodo-2-oxo-2,3-dihydro-lH-indol-l- yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-mdol-I-yl)acetamide; 2-(5,7-dibromo- 2-oxo-2, 3-dihydro- lH-indol- l-yl)acetamide; 2-(5-nitro-2-oxo-2,3-dihydro- lH-indol- 1 - yl)acetamide; 2-(5-methyl-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide; 2-(5-chloro-2- oxo-2,3-dihydro-lH-indol-l-yl)propanamide; (2R)-2-(5-chloro-2-oxo-2, 3-dihydro- 1H- indol-l-yl)propanamide; (2S)-2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l- yUpropanamide; 2-[2-oxo-5-(trifluoromethoxy)-2, 3-dihydro- lH-indol- l-yl]acetamide; 2- (5-isopropyl-2-oxo-2, 3-dihydro- lH-indol- l-yl)acetamide; 2-(5-ethyl-2-oxo-2,3-dihydro- lH-indol-l-yl)acetamide; 2-(5-fluoro-2-oxo-2,3~dihydro-lH-indol-l-yl)acetamide; 2- (5,7-dimethyl-2-oxo-2,3-dihydro-lH-jττdol-l-yl)acetarnide; 2-(5-bromo-2-oxo-2,3- dihydro-lH-indol-l-yl)acetamide; 2-(2-oxo-5-propyl-2,3-dihydro-lH-indol-l- yl)acetamide; 2-[2-oxo-5-(trifluoromethyl)-2,3-dihydro-lH-indol-l-yl]acetarnide; 2-(5,6- dj nethyl-2-oxo-2,3-dihydro-lH-jτιdol-l-yl)acetamide; 2-(7-chloro-2-oxo-2,3-dihydro- lH-indol-l-yl)acetamide; 2-(6-chloro-2-oxo-2,3-dmydro-lH-indol-l-yl)acetamide; 2-(5- chloro-2-oxo-2, 3-dihydro- lH-indol-l-yl)butanarnide; (+)-2-(5-chloro-2-oxo-2,3- dihydro-lH-indol-l-yl)butanamide; (-)-2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol-1- yl)butanamide; 2-(5-methyl-2-oxo-2, 3-dihydro- lH-indol- l-yl)propanamide; (+)-2-(5- methyl-2-oxo-2 , 3-dihydro- 1 H-indol- 1 -yl)propanamide; (-) -2- (5-methyl-2-oxo-2 , 3- dmydro-lH-indol-l-yl)propanamide; 2-(5-bromo-2-oxo-2,3-dihydro-lH-indol-l- yUpropanamide; (-)-2-(5-bromo-2-oxo-2, 3-dihydro- lH-indol- 1 -yl)propanamide; (+)-2- (5-bromo-2-oxo-2,3-d ydro-lH-mdol-l-yl)propanarnide; 2-(5-chloro-7-fluoro-2-oxo- 2,3-dihydro- lH-indol- l-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro- lH-indol- l-yl)-N- (3-hydroxyphenyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-(3- fluorophenyl)acetarnide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[3-(2-pyridin- 2-ylethyl)phenyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[6- (hydroxymethyl)cyclohex-3-en- l-yl]acetamide; 5-chloro- l-[2-oxo-2-(4-pyridin-2- ylpiperazin-l-yl)ethyl]-l,3-dihydro-2H-indol-2-one; 5-chloro- 1 -{2- [4- (3- ιnethylphenyl)piperazin-l-yl]-2-oxoethyl}-l,3-dihydro-2H-indol-2-one; 2-(5-chloro-2- oxo-2,3-dι τydro-lH-indol-l-yl)-N-(4-hydroxy-3-rnethoxybenzyl)acetarnide; 2-(5-chloro- 2-oxo-2,3-djjιydro-lH-indol-l-yl)-N-(pyridin-4-ylmethyl)-N-(tetrahydrofuran-2- ylxnethyUacetamide; 5-chloro-l-[2-(3-hydroxypiperidin-l-yl)-2-oxoethyl]-l,3-dihydro- 2H-indol-2-one; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- l-yl)-N'- isonicotinoylacetohydrazide; 5-chloro- l-(2-oxo-2-thiomorpholin-4-ylethyl)- 1 ,3-dihydro- 2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-lH-mdol-l-yl)-N-(4H-l>2,4-triazol-3- yDacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[4- (m.eτJτylsuffonyl)benzyl]acetarnide; l-[(5-chloro-2-oxo-2,3-dihydro-lH-indol-l- yl)acetyl]octahydroquinolin-4(lH)-one; N'-(4-bromophenyl)-2-(5-chloro-2-oxo-2,3- dihydro-lH-indol-l-yl)acetohydrazide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol-l-yl)-N- (6-niethoxypyridm-3-yl)acetamide; N-butyl-2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- 1 - yl)acetamide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol-l-yl)-N-(3- hydroxypropyUacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[3-
(dinιethylamino)propyl]acetamide; 5-chloro- l-{2-oxo-2-[4-(2-phenylethyl)piperazin- 1- yl]ethyl}-l,3-dihydro-2H-indol-2-one; ethyl {[(5-chloro-2-oxo-2,3-dihydro-lH-indol-l- yl)acetyl]amino}acetate; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-(3- etτιoxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-(2- fluoroethyl)acetarnide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-methoxy-N- methylacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-(3,4- dimethylphenyljacetamide; N-(4-tert-butylphenyl)-2-(5-chloro-2-oxo-2, 3-dihydro- 1H- indol-l-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-(3-hydroxy-2,2- dimethylpropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[l- (hydroxymethyl)propyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-IH-indol-l-yl)-N-
(3,3,3-trifluoro-2-hydroxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l- yl)-N-(2-hydroxy-2-phenylethyl)acetamide; 5-chloro-l-{2-[4-(4- hydroxyphenyUpiperazin- l-yl]-2-oxoethyl}- 1 ,3-dihydro-2H-indol-2-one; 2-(5-chloro-2- oxo-2, 3-dihydro- lH-indol- 1 -yl)-N-(pyridin-4-ylmethyl)acetamide; 2-(5-chloro-2-oxo- 2, 3-dihydro- lH- dol-l-yl)-N-[(5-jmethyl-2-fuj^l)methyl]acetamide; 2-(5-chloro-2-oxo- 2,3-dihydro-lH-indol-l-yl)-N-[3-(lH-pyrazol-l-yl)propyl]acetamide; methyl 3-[(5- cUoro-2-oxo-2,3-dj ιydro-lH-indol-l-yl)acetyl]-l,3-t azolidine-4-carboxylate; 5- chloro- l-[2-(2,5-dihydro- lH-pyrrol- l-yl)-2-oxoethyl]- 1 ,3-dihydro-2H-indol-2-one; 2-(5- cMoro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N'-(4,5-dihydro-lH-irxιidazol-2- yl)acetohydrazide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- 1 -yl)-N-[2-(3,4- dimethoxyphenyUethyllacetairjide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[2- (2-cMorophenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol-l-yl)-N-[2-(4- methylphenyl)ethyl]acetarnide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- l-yl)-N-(2- ιnoj holin-4-ylethyl)acetamide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- l-yl)-N-[2- (3,4,5,6-teτrahydro-l-benzazocin-l(2H)-yl)propyl]acetaιιιide; 2-(5-chloro-2-oxo-2,3- dihydro-lH-indol-l-yl)-N-[2-{2-methylpiperidm-l-yl)ethyl]acetamide; 2-(5-chloro-2- oxo-2,3-dihydro-lH-indol- l-yl)-N-(2-nitroberιzyl)acetamide; 2-(5-chloro-2-oxo-2,3- dihydro- lH-indol- 1 -yl)-N-(3,4-dihydro- lH-isochromen- l-ylιnethyl)acetarnide; N-(2- chloro-6-fluorobenzyl)-2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetarrιide; N- benzyl-2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- 1 -yl)-N-methylacetamide; 2-(5-chloro- 2-oxo-2,3-d ydro-lH-indol-l-yl)-N-{2-[(tτ uorometlιyl)thio]benzyl}acetamide; 5- chloro-l-[2-(l,4-dioxa-8-azaspjχo[4.5]dec-8-yl)-2-oxoethyl]-l,3-dihydro-2H-indol-2- one; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-cycloheptylacetamide; 5-chloro-l- {2-[4-(2-nιorphoJ Q-4-ylethyl)piperazm-l-yl]-2-oxoethyl}-l,3-dihydro-2H-indol-2-one; and 2-(5-cMoro-2-oxo-2,3-dj iydro-lH-indol-l-yl)-N-pyridin-3-ylacetamide.
More preferred compounds are: 2-(5-iodo-2-oxo-2, 3-dihydro- lH-indol-1- yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide; 2-(5,7-dibromo- 2-oxo-2,3-dihydro- lH-indol- l-yl)acetamide; (2S)-2-(5-chloro-2-oxo-2,3-dihydro- 1H- indol-l-yl)propanamide; 2-[2-oxo-5-(trifluorornethyl)-2,3-dihydro-lH-indol-l- yl]acetarnide and 2-(5-cMoro-7-fluoro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetarnide.
In a most preferred embodiment the invention relates to a compound selected from 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide and (2S)-2-(5-chloro-2- oxo-2,3-dihydro-'lH-indol-l-yl)propanamide.
The "pharmaceutically acceptable salts" according to the invention include therapeutically active, non-toxic base salt forms which the compounds of formula I are able to form. The compounds of formula I containing acidic protons may be converted into their therapeutically active, non-toxic base addition salt forms, e.g. metal or amine salts, by treatment with appropriate organic and inorganic bases. Appropriate base salt forms include, for example but not limited to, ammonium salts, alkali and earth alkaline metal salts, e.g. lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. N-methyl-D-glucarnine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
Conversely said salt forms can be converted into the free forms by treatment with an appropriate acid.
Compounds of the formula I and their salts can be in the form of a solvate, which is included within the scope of the present invention. Such solvates include for example hydrates, alcoholates and the like. Many of the compounds of formula I and some of their intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem., 45 (1976) 11-30.
The invention also relates to all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds of formula I or mixtures thereof (including all possible mixtures of stereoisomers).
Some of the compounds of formula I may also exist in tautomeric forms. Such forms although not explicity indicated in the above formula are intended to be included within the scope of the present invention. With respect to the present invention reference to a compound or compounds is intended to encompass that compound in each of its possible isomeric forms and mixtures thereof unless the particular isomeric form is referred to specifically.
Compounds according to the present invention may exist in different polymorphic forms. Although not explicitly indicated in the above formula, such forms are intended to be included within the scope of the present invention.
The compounds of formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry.
A. According to one embodiment, some compounds having the general formula
I may be prepared by desulfurization of a compound of formula II according to the equation:
Figure imgf000014_0001
This reaction may be carried out using Raney nickel in an inert solvent, preferably THF, at a temperature comprised between 0 °C and 40 °C, or as described in: Mehta L., Parrick J., Payne F., J. Chem. Research (S) (1998), 190-191.
Compounds of formula II may be prepared by alkylation of a compound of formula III with a compound of formula IV according to the equation:
Figure imgf000015_0001
wherein Hal is a halogen atom, preferably Br or CI, and R , R2, R3, R3a, R4( R and R7 have the same definitions as described above.
This reaction may be carried out with a strong base, for example sodium hydride, at a temperature comprised between 0 and 40 °C and in an inert solvent, for example DMF under an inert atmosphere, or as described in patent GB 1,309,692 (UCB).
Compounds of formula III may be prepared by reaction of a compound of formula V with 1,2-ethanedithiol according to the equation:
Figure imgf000015_0002
wherein R4, R^ and R7 have the same definitions as described above.
This reaction may be carried out at a temperature comprised between 25 and 100 °C in an inert solvent or in acetic acid, in the presence of a Lewis acid, preferably BF3-Et2θ under an inert atmosphere.
Compounds of formula V are commercially available or may be prepared according to methods described in: Smith K., El-Hiti G.A., Hawes A.C., Synlett (1999), 945-947; Lackey K., Sternbach D.D., Synthesis (1993), 10, 993; or Organic Synthesis, Collective Volume I, Second Edition, Gilman H. & Blatt A.H., J. Wiley & Sons Inc., 327-330.
B. According to another embodiment, some compounds having the general formula I may be prepared by oxidative bromination of the corresponding indole of formula (VI) followed by the reduction of compound (VII) according to the equation:
Figure imgf000015_0003
This reaction may be carried out as described in: Marfat A., Carta M.P., Tetrahedron Lett. (1987), 28, 4027-4031.
Compounds of formula VI may be prepared by alkylation of a compound of foimula VIII with a compound of formula IV according to the equation:
Figure imgf000016_0001
wherein Hal is an halogen atom, preferably Br or CI.
This reaction may be carried out in the presence of a strong base, preferably sodium hydride, at a temperature comprised between 0 and 40 °C, in an inert solvent, for example DMF, under an inert atmosphere, or as described in patent GB 1,309,692 (UCB).
•. C. According to another embodiment, some compounds having the general formula I may be prepared by halogenation of the corresponding compound of formula
I wherein R^ is a hydrogen^with a N-halosuccinirnide according to the procedure described in: Castanet A.-S., Colobert F., Broutih P.-E., Tetrahedron Lett. (2002), 43,
5047-5048.
According to another embodiment, some compounds having the general formula I may be prepared analogously from the corresponding compound of formula I wherein R^ = R7 = H by using two equivalents of N-halosuccinimide.
D. According to another embodiment, some compounds having the general formula I may be prepared by nitration of the corresponding compound of formula I wherein is a hydrogen according to procedure described in: Sun L., Rubin J.R., Kraker A.J., Showalter H.D., J. Heterocyclic Chem. (1997), 34, 1399-1405.
E. According to another embodiment, some compounds having the general formula I may be prepared by coupling of an amine of formula NHR R3a with a carboxylic acid derivative of formula IX in the presence of a coupling agent such as dicyclohexylcarbodiimide in dichloromethane or THF.
Figure imgf000017_0001
(IX) (I)
In one embodiment, the present invention concerns also the synthesis intermediates of formula II or stereoisomeric forms thereof,
Figure imgf000017_0002
wherein
R! is hydrogen,
R2 is hydrogen or Cl-20-alkyl,
R3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°,
R3a is hydrogen, Cl-20-alkyl or a group of formula:
Figure imgf000017_0003
or NR3R3a is a group of formula
Figure imgf000017_0004
R4 is hydrogen,
R^ is hydrogen; nitro; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl;
-Sθ2-CI-4-alkyl; -SONH2; Cl-20-alkyl unsubstituted or substituted by halogen; or
Cl-20-alkoxy unsubstituted or substituted by halogen,
R is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, Cl-20-alkyl or halogen,
W is Cl-12-alkylene, -NH- or -NHC(=0)-,
X is O, S or NH, Y is O, S, -CR12Rl3-, -NR14- or -C(=0)-,
Rβ is aryl or heterocycle,
Rp, RIO,
Figure imgf000018_0001
R11 gj-g independently selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R O and RlOa together form a C3-6-alkylene,
R^ is hydrogen, Cl-4-alkyl, halogen or hydroxy,
R 3 is hydrogen, or CR12R1 is dioxolanyl,
R!4 is aryl, heterocycle or a group of formula - -R-Α
V is Cl-12-alkylene,
R^° is aryl or heterocycle, m is 1 to 4, n is O or 1 , and at least one of R^, R^ or R7 is different from hydrogen when R2 is hydrogen, R3 is
H or 2,6-diisopropylphenyl, and R3a is H.
In another embodiment, the present invention concerns also the synthesis intermediates of formula II or stereoisomeric forms thereof,
Figure imgf000018_0002
wherein
R! is hydrogen,
R2 is hydrogen or Cl-20-alkyl,
R3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°,
R a is hydrogen, Cl-20-alkyl or a group of formula:
L Jrrι \
or NR3R3a is a group of formula 7.
Figure imgf000018_0003
R4 is hydrogen, R5 is hydrogen; nitro; halogen; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen,
R6 is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, Cl-20-alkyl or halogen, W is Cl-12-alkylene, -NH- or -NHC(=0)-,
X is O, S or NH,
Y is O, S, -CR12Rl3-, -NR14- or -C(=0)-,
R is aryl or heterocycle, , R!0> RlOa and pll ^Q independenlty selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or RIO a d RlOa together form a C3-6-alkylene,
Rl is hydrogen, Cl-4-alkyl, halogen or hydroxy,
R*3 is hydrogen, or CR*2R13 is dioxolanyl, R 4 is aryl, heterocycle or a group of formula -V-R^^,
V is Cl-12-alkylene,
Rl° is aryl or heterocycle, m is 1 to 4, n is 0 or 1, and at least one of Rβ, R6 or R7 is different from hydrogen when R2 is hydrogen, R3 is
H or 2,6-diisopropylphenyl, and R3a is H.
Preferably, the synthesis intermediates of formula II are selected from the group consisting of: 2-(5'-methyl-2'-oxospiro[l,3-dithiolane-2,3'-indol]-l'(2'H)- yljacetamide; 2-[2'-oxo-5'-[(tr uoromethyl)oxy]spiro[l,3-dithiolane-2)3,-indol]-l,(2'H)- yl]acetaιmde; 2-[5'-(l-methylemyl)-2,-oxospiro[l,3-di1±iolane-2,3'-indol]-l'(2Η)- yljacetamide; 2-(5'-ethyl-2'-oxospfro[l,3-dithiolane-2,3'-indol]-l'(2Η)-yl)acetarπide;
2-(5'-fluoro-2'-oxospiro[l,3-ditMolane-2,3'-mdol]-l'(2Η)-yl)acetamide; 2-(5',7'- dimethyl-2'-oxospiro[l,3-dithiolane-2,3'-indol]-l'(2'H)-yl)acetainide; 2-{2'-oxo-5'- propylspfro[l,3-ditniolane-2,3'-indol]-l'(2Η)-yl)acetamide; 2-[2'-oxo-5'- (trifluoromethyl)spiro[l,3-dit±ύolane-2,3'- dol]-l'(2Η)-yl]acetamide; and 2-(5',6'- diιnethyl-2'-oxospfro[l,3-ditMolane-2,3'-indol]-l'(2Η)-yl)acetaιιιide.
In one embodiment, the invention concerns also the synthesis intermediates of formula III or stereoisomeric forms thereof,
Figure imgf000019_0001
wherein R4 is hydrogen,
R is hydrogen; nitro; azido; cyano, -S-Cl-4-alkyl; -SO-Cl-4-alkyl; -Sθ2-Cl-4-alkyl; -SO H2; Cl-20-alkyl unsubstituted or substituted by halogen; or C 1-20-alkoxy unsubstituted or substituted by halogen, β is hydrogen, Cl-20-alkyl or halogen, R7 is hydrogen, Cl-20-alkyl or halogen, and at least one of R , R^ or R7 is different from hydrogen.
In another embodiment, the invention concerns also the synthesis intermediates of formula III or stereoisomeric forms thereof,
Figure imgf000020_0001
wherein
R4 is hydrogen, β is hydrogen; nitro; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20- alkoxy unsubstituted or substituted by halogen,
R is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, Cl-20-alkyl or halogen, and at least one of R^, R^ or R7 is different from hydrogen.
Preferably, the synthesis intermediates of formula III are selected from the group consisting of: 5'-methylspiro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one; 5'-
[(trifluorornethyl)oxy]spfro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one; 5'-(l- j ethylethyl)spjTo[l,3-dithiolane-2,3'-indol]-2'(l'H)-one; 5'-ethylspiro[l,3-dithiolane-
2,3'-indol]-2'(lΗ)-one; 5'-fluorospiro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one; 5',7'- dimethylspiro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one; 5'-propylspiro[l,3-dithiolane-2,3,- indol]-2'(l'H)-one; 5'-(tr uoromethyl)spfro[l,3-dithiolane-2,3'-indol]-2,(lΗ)-one; and
5 6'-dimethylspfro[l,3-dithiolane-2,3'-indol]-2'(I'H)-one.
In one embodiment, the present invention concerns also the synthesis intermediates of formula VI or stereoisomeric forms thereof,
Figure imgf000020_0002
wherein
R! is hydrogen,
R2 is hydrogen or Cl-20-alkyl,
R3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°,
R a is hydrogen, Cl-20-alkyl or a group of formula:
'X^ 8
R or NR R a is a group of formula:
Figure imgf000021_0001
R4 is hydrogen,
R5 is hydrogen; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl;
-S02-Cl-4-alkyl; -SONH2; or Cl-20-alkyl unsubstituted or substituted by halogen,
R is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, C2-20-alkyl or halogen, W is Cl-12-alkylene, -NH- or -NHC(=0)-,
X is O, S or NH,
Y is O, S, -CR12R13-, -NR14- or -C(=0)-, β is aryl or heterocycle,
R9, R10, R10a and R1 1 are independenlty selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R10 and Rl°a together form a C3-6-alkylene,
R* is hydrogen, Cl-4-alkyl, halogen or hydroxy,
R 3 is hydrogen, or CR^2R13 is dioxolanyl, Rl4 is aryl, heterocycle or a group of formula -V-R-Α
V is Cl-12-alkylene,
R\5 is aryl or heterocycle, m is 1 to 4, n is 0 or 1 , and at least one of R^, Rβ or R7 is different from hydrogen when R2 is hydrogen, R3 is
H or 2,6-diisopropylphenyl, and R a is H.
In another embodiment, the present invention concerns the synthesis intermediates of formula VI or stereoisomeric forms thereof,
Figure imgf000022_0001
wherein R! is hydrogen, R2 is hydrogen or Cl-20-alkyl,
R3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R°, R a is hydrogen, Cl-20-alkyl or a group of formula:
Figure imgf000022_0002
or NR3R a is a group of formula:
Figure imgf000022_0003
R4 is hydrogen,
Rβ is hydrogen; halogen; or Cl-20-alkyl unsubstituted or substituted by halogen,
R6 is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, C2-20-alkyl or halogen,
W is Cl-12-alkylene, -NH- or -NHC(=0)-,
X is O, S or NH,
Y is O, S, -CR12R13-, -NR14- or -C(=0)-,
Rβ is aryl or heterocycle,
Rβ, R10, Rl°a and R11 are independenlty selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R10 and R10a together form a C3-6-alkylene,
R 2 is hydrogen, Cl-4-alkyl, halogen or hydroxy,
R* is hydrogen, or CR^R-*- is dioxolanyl,
R-*-4 is aryl, heterocycle or a group of formula -V-R-Α
V is Cl-12-alkylene,
RIS is aiyl or heterocycle, m is 1 to 4, n is 0 or 1 , and at least one of R , Rβ or R7 is different from hydrogen when R2 is hydrogen, R3 is
H or 2,6-diisopropylphenyl, and R3a is H.
Preferably, the synthesis intermediates of formula VI are selected from the group consisting of : 2-(5-chloro-lH-indol-l-yl)propanamide;
2-(7-cMoro-lH-indol-l-yl)acetamide; 2-(6-cMoro-lH-indol-l-yl)acetarnide, 2-(5-chloro-lH-mdol-l-yl)butanamide; 2-(5-methyl-lH-indol-l-yl)propanamide; 2-(5- bromo-lH-indol-l-yl)propanamide; 2-(7-fluoro-lH-indol-l-yl)acetamide; 2-(5-bromo- lH-indol-l-yl)acetamide; 2-(5-fluoro-lH-indol-l-yl)acetamide; and 2-(5-chloro-lH- indol-l-yl)acetamide.
In one embodiment, the present invention concerns also the synthesis intermediates of formula DC or stereoisomeric forms thereof,
Figure imgf000023_0001
wherein R! is hydrogen,
R2 is hydrogen or Cl-20-alkyl,
R4 is hydrogen, β is hydrogen; nitro; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl;
-Sθ2-Cl-4-alkyl; -SONH2; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen,
Rβ is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, Cl-20-alkyl or halogen, and at least one of R^, R^ or R7 is different from hydrogen when R2 is hydrogen, R3 is
H or 2,6-diisopropylphenyl, and R a is H. In another embodiment, the present Invention concerns the synthesis intermediates of formula IX or stereoisomeric forms thereof,
Figure imgf000023_0002
wherein
R)- is hydrogen, R2 is hydrogen or Cl-20-alkyl, R4 is hydrogen,
R5 is hydrogen; nitro; halogen; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen, R is hydrogen, Cl-20-alkyl or halogen, R7 is hydrogen, Cl-20-alkyl or halogen, and at least one of Rβ, Rβ or R7 is different from hydrogen when R2 is hydrogen, R3 is H or 2,6-diisopropylphenyl, and R3a is H.
Preferably, the synthesis intermediate of formula IX is (5-chloro-2-oxo-2,3- dihydro-lH-indol-l-yl)acetic acid.
The present invention also concerns the synthesis intermediates 2-(7-fluoro-2- oxo-2,3-dihydro-lH-indol-l-yl)acetamide and ethyl (5-chloro-2-oxo-2,3-dihydro-lH- indol- 1 -yl) acetate .
It has now been found that compounds of formula I and their pharmaceutically acceptable salts are useful in a variety of pharmaceutical indications.
For example, the compounds according to the invention are useful for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsions.
These compounds may also be used for the treatment of Parkinson's disease.
These compounds may also be used for the treatment of dyskinesia induced by dopamine replacement therapy, tardive dyskinesia induced by administration of neuroleptlc drugs or Huntington Chorea.
In addition, the compounds according to the invention may also be used for treating other neurological disorders including bipolar disorders, mania, depression, anxiety, attention deficit hyperactivity disorder (ADHD), migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythrnla, myotonia, ***e abuse, stroke, myoclonus, tremor, essential tremor, simple or complex tics, Tourette syndrome, restless leg syndrome and other movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitls.
Thus, the present invention also concerns a compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof as defined above for use as a medicament. In a further aspect, the present invention concerns also the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of neurological and other disorders such as mentioned above.
In particular, the present invention concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of epilepsy, Parkinson's disease, dyskinesia, rnigraine, bipolar disorders, chronic pain, neuropathic pain, or bronchial, asthmatic or allergic conditions.
The methods of the invention comprise administration to a mammal (preferably human) suffering from above mentioned conditions or disorders, of a compound according to the invention in an amount sufficient to alleviate or prevent the disorder or condition.
The compound is conveniently adrninistered in any suitable unit dosage form, including but not limited to one containing 3 to 3000 mg, preferably 25 to 500 mg of active ingredient per unit dosage form. The term "treatment" as used herein includes curative treatment and prophylactic treatment.
By "curative" is meant efficacy in treating a current symptomatic episode of a disorder or condition.
By "prophylactic" is meant prevention of the occurrence or recurrence of a disorder or condition.
The term "epilepsy" as used herein refers to a chronic neurologic condition characterised by unprovoked, recurrent epileptic seizures. An epileptic seizure is the manisfestation of an abnormal and excessive synchronised discharge of a set of cerebral neurons; its clrnlcal manifestations are sudden and transient. The term "epilepsy" as used herein can also refer to a disorder of brain function characterised by the periodic occurrence of seizures. Seizures can be "nonepileptic" when evoked in a normal brain by conditions such as high fever or exposure to toxins or "epileptic" when evoked without evident provocation.
The term "seizure" as used herein refers to a transient alteration of behaviour due to the disordered, synchronous, and rhythmic firing of populations of brain neurones.
The term "Parkinsonian symptoms" relates to a syndrome characterized by slowness of movement (bradykinesia), rigidity and / or tremor. Parkinsonian symptoms are seen in a variety of conditions, most commonly in idiopathic Parkinsonlsm (i.e. Parkinson's Disease) but also following treatment of schizophrenia, exposure to toxins/drugs and head injury. It is widely appreciated that the primary pathology underlying Parkinson's disease is degeneration, in the brain, of the dopamlnergic projection from the substantia nigra to the striatum. This has led to the widespread use of dopamine-replacing agents (e.g. L-3,4-dihydroxyphenylalanlne (L- DOPA) and dopamlne agonists) as symptomatic treatments for Parkinson's disease and such treatments have been successful in increasing the quality of life of patients suffering from Parkinson's disease. However, dopamine-replacement treatments do have limitations, especially following long-term treatment. Problems can include a wearing-off of the anti-parkinsonian efficacy of the treatment and the appearance of a range of side-effects which manifest as abnormal involuntary movements, such as dyskinesias. The term "dyskinesia" is defined as the development in a subject of abnormal involuntary movements. This appears in patients with Huntington's disease, in Parkinson's disease patients exposed to chronic dopamine replacement therapy, and in Schizophrenia patients exposed to chronic treatment with neuroleptics. Dyskinesias, as a whole, are characterised by the development in a subject of abnormal involuntary movements. One way in which dyskinesias may arise is as a side effect of dopamine replacement therapy for parklnsonism or other basal ganglia- related movement disorders.
The term "migraine" as used herein means a disorder characterised by recurrent attacks of headache that vary widely in intensity, frequency, and duration. The attacks are commonly unilateral and are usually associated with anorexia, nausea, vomiting, phonophobia, and/or photophobia. In some cases they are preceded by, or associated with, neurological and mood disturbances. Migraine headache may last from 4 hours to about 72 hours. The International Headache Society (IHS, 1988) classifies migraine with aura (classical migraine) and migraine without aura (common migraine) as the major types of migraine. Migraine with aura consists of a headache phase preceded by characteristic visual, sensory, speech, or motor symptoms. In the absence of such symptoms, the headache is called migraine without aura.
The term "bipolar disorders" as used herein refers to those disorders classified as Mood Disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TM), American Psychiatry Association, Washington, DC, 1994). Bipolar disorders are generally characterised by spontaneously triggered repeated (i.e. at least two) episodes in which the patient's hyperexcitability, activity and mood are significantly disturbed, this disturbance consisting on some occasions of an elevation of mood and increased energy and activity (mania or hypomania), and in other occasions a lowering of mood and decreased energy and activity (depression). Bipolar disorders are separated into four main categories in the DSM-IV (bipolar I disorder, bipolar II disorder, cyclotnymia, and bipolar disorders not otherwise specified).
The term "manic episode", as used herein refers to a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood with signs of pressured speech and psychomotor agitation. The term "hypomanla", as used herein refers to a less extreme manic episode, with lower grade of severity.
The term "major depressive episode", as used herein refers to a period of at least 2 weeks during which there is either depressed mood or the loss of interest or pleasure in nearly all activities with signs of impaired concentration and psychomotor retardation.
The term "mixed episode", as used herein refers to a period of time (lasting at least 1 week) in which the criteria are met both for a manic episode and for a major depressive episode nearly every day.
The term "chronic pain" as used herein refers to the condition gradually being recognised as a disease process distinct from acute pain. Conventionally defined as pain that persists beyond the normal time of healing, pain can also be considered chronic at the point when the individual realises that the pain is going to be a persistent part of their lives for the foreseeable future. It is likely that a majority of chronic pain syndromes involves a neuropathic component, which is usually harder to treat than acute somatic pain.
The term "neuropathic pain" as used herein refers to pain due to a dysfunctional nervous system, sometimes occurring following injury to the central nervous system (central pain), but more often caused by damage to peripheral nerves (painful peripheral neuropathy). Neuropathic pain is most likely caused by neural hyperexcitatlon in partially damaged nerves. Several types of painful peripheral neuropathy, which may share some underlying pathogenic mechanisms, have been distinguished , such as: (1) postraumatic painful peripheral neuropathy; (2) phantom limb pain; (3) facial (trigeminal) pains; (4) postherpetic neuralgia; (5) painful diabetic neuropathy; (6) neuropathies due to cancer tumors; (7) neuropathies Induced by treatment with anti-neoplastic agents; and (8) nerve damage associated with demyejjnating disease, such as multiple sclerosis. In neuropathic pain, painful reactions appear in response to normally neutral stimuli (allodynia) or as exaggerated reactions to painful stimuli (hyperalgesia). Spontaneous pain, not provoked by external stimuli, also occurs in neuropathic pain, and is the most difficult form of pain to measure and treat.
The term "tics" refers to common and often disabling neurological disorders. They are frequently associated with behaviour difficulties, including obsessive- compulsive disorder, attention deficit hyperactivity disorder and impulse control. Tics are involuntary, sudden, rapid, repetitive, nonrhythrnic stereotype movements or vocalizations. Tics are manifested in a variety of forms, with different durations and degrees of complexity. Simple motor tics are brief rapid movements that often involve only one muscle group. Complex motor tics are abrupt movements that involve either a cluster of simple movements or a more coordinated sequence of movements. Simple vocal tics include sounds such as grunting, barking, yelping, and thoat clearing. Complex vocal tics include syllables, phrases, repeating other people's words and repeating one's own words. The term "tremor" refers to an involuntary, rhythmical, oscillatory movement of a body part. Tremor can be phenomenologically defined as tremor at rest or associated with an action. Such an action can be postural (maintenance of a limb position), kinetic (movement-related), or intentional (at the end of a purposeful movement). Etlologically, tremor most often occurs in Parkinson's disease (Parkinsonian rest tremor) and in essential tremor (postural and kinetic tremor), which consists of hereditary and age-related forms. Tremor may also occur in dystonia and in multiple sclerosis. Other tremors, which can arise from various etiologies, are cerebellar (intentional tremor) and Holmes' midbrain tremor (postural tremor). Tremor can also be an exaggerated form of normal physiological tremor. Apart from the behavioral context in which tremor occurs, tremor frequency is an important criterion to distinguish between various forms of tremor. Essential tremor has the highest incidence of all tremors. As it is age-related, it can be expected to increase in aging populations. Animal model and clinical data indicate that essential tremor may be primarily based on a brainstem (inferior olivary nucleus) - cerebellar dysfunction, whereas Parkinsonian tremor probably originates from abnormal activity within the basal ganglia. Excessive synchronization and/or hyperexcitation in neuronal circuits may underlie tremor activity.
The activity of the compounds of formula I, or their pharmaceutically acceptable salts, as anticonvulsants can be determined in the audiogenic seizures model. The objective of this test is to evaluate the anticonvulsant potential of a compound by means of audiogenic seizures induced in sound-susceptible mice, a genetic animal model with reflex seizures. In this model of primary generalised epilepsy, seizures are evoked without electrical or chemical stimulation and the seizure types are, at least in part, sirriilar n their clinical phenomenology to seizures occurring in man (Lδscher W. & Schmidt D., Epilepsy Res. (1998), 2, p. 145-181;
Buchhalter J.R., Epilepsia (1993), 34, S31-S41). Results obtained with compounds of formula I are indicative of a strong pharmacological effect. Another assay indicative of potential anticonvulsant activity is binding to levetiracetam binding site (LBS) as hereinafter described.
Activity in any of the above-mentioned indications can of course be deterrnined by carrying out suitable clinical trials in a manner known to a person skilled in the relevant art for the particular indication and/or in the design of clinical trials in general.
For treating diseases, compounds of formula I or their pharmaceutically acceptable salts may be employed at an effective daily dosage and adjOjinistered in the form of a pharmaceutical composition. Therefore, another embodiment of the present invention concerns a pharmaceutical composition comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable diluent or carrier.
To prepare a pharmaceutical composition according to the invention, one or more of the compounds of formula I or a pharmaceutically acceptable salt thereof is intimately admixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical compounding techniques known to the skilled practitioner.
Suitable diluents and carriers may take a wide variety of forms depending on the desired route of administration, e.g., oral, rectal, parenteral or intranasal. Pharmaceutical compositions comprising compounds according to the invention can, for example, be adininistered orally or parenterally, i.e., intravenously, intramuscularly or subcutaneously, intrathecally, by inhalation or intranasally.
Pharmaceutical compositions suitable for oral administration can be solids or liquids and can, for example, be in the form of tablets, pills, dragees, gelatin capsules, solutions, syrups, chewing-gums and the like.
To this end the active ingredient may be mixed with an inert diluent or a non- toxic pharmaceutically acceptable carrier such as starch or lactose. Optionally, these pharmaceutical compositions can also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatine, a disfntegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetener such as sucrose or saccharin, or colouring agents or a flavouring agent such as pepperinlnt or methyl salicylate.
The invention also contemplates compositions which can release the active substance in a controlled manner. Pharmaceutical compositions which can be used for parenteral adrnlnistration are in conventional form such as aqueous or oily solutions or suspensions generally contained in ampoules, disposable syringes, glass or plastics vials or infusion containers. In addition to the active Ingredient, these solutions or suspensions can optionally also contain a sterile diluent such as water for injection, a physiological saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulphite, chelating agents such as ethylene diamine-tetra-acetle acid, buffers such as acetates, citrates or phosphates and agents for adjusting the osmolarity, such as sodium chloride or dextrose.
These pharmaceutical forms are prepared using methods which are routinely used by pharmacists. The amount of active ingredient in the pharmaceutical compositions can fall within a wide range of concentrations and depends on a variety of factors such as the patient's sex, age, weight and medical condition, as well as on the method of admimstration. Thus the quantity of compound of formula I in compositions for oral administration is at least 0.5 % by weight and can be up to 80 % by weight with respect to the total weight of the composition.
In accordance with the invention it has also been found that the compounds of formula I or the pharmaceutically acceptable salts thereof can be administered alone or in combination with other pharmaceutically active ingredients. Non-limiting examples of such additional compounds which can be cited for use in combination with the compounds according to the invention are antivirals, antispastlcs (e.g. baclofen), antiemetics, antimanic mood stabilizing agents, analgesics (e.g. aspirin, ibuprofen, paracetamol), narcotic analgesics, topical anesthetics, opioid analgesics, lithium salts, antidepressants (e.g. mlanserin, fluoxetine, trazodone), tricyclic antidepressants (e.g. xnipramine, desipramlne), anticonvulsants (e.g. valproic acid, carbamazeplne, phenytoin), antipsychotics (e.g. risperidone, haloperidol), neuroleptics, benzodiazepines (e.g. diazepam, clonazepam), phenothiazines (e.g. chlorpromazine), calcium channel blockers, amphetamine, clonidine, lidocaine, mexfletlne, capsaicln, caffeine, quetiapine, serotonin antagonists, β-blockers, antiarrhythrnics, triptans, ergot derivatives and amantadlne. Of particular Interest In accordance with the present invention are combinations of at least one compound of formula I or a pharmaceutically acceptable salt thereof and at least one compound inducing neural inhibition mediated by GABA^ receptors. The compounds of formula I exhibit a potentiating effect on the compounds inducing neural inhibition mediated by GABA^ receptors enabling, in many cases, effective treatment of conditions and disorders under reduced risk of adverse effects. Examples of compounds inducing neural inhibition mediated by GABA^ receptors include the following: benzodiazepines, barbiturates, steroids, and anticonvulsants such as valproate, viagabatrine, tiagabine or pharmaceutical acceptable salts thereof.
Benzodiazepines include the 1,4-benzodiazepines, such as diazepam and clonazepam, and the 1,5-benzodiazepines, such as clobazam. Preferred compound is clonazepam.
Barbiturates include phenobarbital and pentobarbital. Preferred compound is phenobarbital.
Steroids include adrenocortlcotropic hormones such as tetracosactide acetate, etc. Anticonvulsants include hydantoins (phenytoin, ethotoin, etc), oxazolidines
(trirnethadione, etc.), succini ides (ethosuxtrnide, etc.), phenacemldes (phenacemlde, acetylpheneturide, etc.), sutfonamides (sulthlame, acetoazolamide, etc.), aminobutyric acids (e.g. garnrna-amino-beta-hydroxybutyric acid, etc.), sodium valproate and derivatives, carbamazeplne and so on. Preferred compounds include valproic acid, valpromide, valproate pivoxil, sodium valproate, semi-sodium valproate, divalproex, clonazepam, phenobarbital, vigabatrine, tiagabine and amantadine.
Of particular interest in accordance with the present invention are combinations of at least one compound of formula I or a pharmaceutically acceptable salt thereof and at least one compound modulating neurotransrnission mediated by glutamate receptors. The compounds of formula I exhibit a potentiating effect on the compounds modulating neurotransrnission mediated by glutamate receptors enabling, in many cases, effective treatment of conditions and disorders under reduced risk of adverse effects. Examples of compounds modulating neurotransrnission mediated by glutamate receptors include the following: NBQX and MK-801 or pharmaceutical acceptable salts thereof.
For the preferred oral compositions, the daily dosage is in the range 3 to 3000 rrtilligra s (mg) of compounds of formula I. In compositions for parenteral administration, the quantity of compound of formula I present is at least 0.5 % by weight and can be up to 33 % by weight with respect to the total weight of the composition. For the preferred parenteral compositions, the dosage unit is in the range 3 mg to 3000 mg of compounds of formula I. The daily dose can fall within a wide range of dosage units of compound of formula I and is generally in the range 3 to 3000 mg. However, it should be understood that the specific doses can be adapted to particular cases depending on the individual requirements, at the physician's discretion.
The LBS binding compounds provided by this invention and labelled derivatives thereof may be useful as standards and reagents in detexn irilng the ability of tested compounds (e.g., a potential pharmaceutical) to bind to the LBS receptor.
Labelled derivatives of LBS ligands provided by this invention may also be useful as radiotracers for positron emission tomography (PET) imaging or for single photon emission computerized tomography (SPECT).
The following examples are provided for illustrative purposes. Unless specified otherwise in the examples, characterization of the compounds is performed according to the following methods:
NMR spectra are recorded on a BRUKER AC 250 Fourier Transform NMR Spectrometer fitted with an Aspect 3000 computer and a 5mm
Figure imgf000032_0001
dual probehead or BRUKER DRX 400 FT NMR fitted with a SG Indigo2 computer and a 5 mm inverse geometry ^-K/^C/^N triple probehead. The compound is studied in DMSO-dg .(or CDCI3) solution at a probe temperature of 313 K or 300 K and at a concentration of 20 mg/ml. The instrument is locked on the deuterium signal of DMSO-dg (or CDCI3). Chemical shifts are given in ppm downfield from TMS taken as internal standard. HPLC analyses are performed using one of the following systems:
- an Agilent 1100 series HPLC system mounted with an INERTSIL ODS 3 C18, DP 5 μm, 250 X 4.6 mm column. The gradient runs from 100 % solvent A (acetonitrile, water, H3PO4 (5/95/0.001, v/v/v)) to 100 % solvent B (acetonitrile, water, H3PO4 (95/5/0.001, v/v/v)) in 6 min with a hold at 100 % B of 4 min. The flow rate is set at 2.5 i i/rnin. The chromatography is carried out at 35°C.
- a HP 1090 series HPLC system mounted with a HPLC Waters Symetry C18, 250 X 4.6 mm column. The gradient runs from 100 % solvent A (MeOH, water, H3PO4 (15/85/0.001M, v/v/M)) to 100 % solvent B (MeOH, water, H3PO4 (85/15/0.001 M, v/v/M)) in 10 min with a hold at 100 % B of 10 min. The flow rate is set at 1 i /rnin. The chromatography is carried out at 40 °C.
Mass spectrometric measurements in LC/MS mode are performed as follows: HPLC conditions
Analyses are performed using a WATERS Alliance HPLC system mounted with an INERTSIL ODS 3, DP 5 μm, 250 X 4.6 mm column. The gradient runs from 100 % solvent A (acetonitrile, water, TFA (10/90/0.1, v/v/v)) to 100 % solvent B (acetonitrile, water, TFA (90/10/0.1, v/v/v)) in 7 min with a hold at 100 % B of 4 min. The flow rate is set at 2.5 ml/min and a split of 1/25 is used just before API source.
MS conditions
Samples are dissolved in acetonitrile/water, 70/30, v/v at the concentration of about 250 μgr/ml. API spectra (+ or -) are performed using a FINNIGAN (San Jose, CA, USA) LCQ ion trap mass spectrometer. APCI source operates at 450 °C and the capillary heater at 160 °C. ESI source operates at 3.5 kV and the capillary heater at 210 °C.
Mass spectrometric measurements In DIP/EI mode are performed as follows: samples are vaporized by heating the probe from 50 °C to 250 °C in 5 min. El
(Electron Impact) spectra are recorded using a FINNIGAN (San Jose, CA, USA) TSQ 700 tandem quadrupole mass spectrometer. The source temperature is set at 150 °C.
Mass spectrometric measurements on a TSQ 700 tandem quadrupole mass spectrometer (Finnigan MAT, San Jose, CA, USA) in GC/MS mode are performed with a gas chromatograph model 3400 (Varian, Walnut Creek, CA, USA) fitted with a split/ splitless injector and a DB-5MS fused-silica column (15 m x 0.25 mm I.D., 1 μm) from J&W Scientific (Folsom, CA, USA). Helium (purity 99.999 %) is used as carrier gas. The injector (CTC A200S autosampler) and the transfer line operate at 290 and 250 °C, respectively. Sample (1 μl) is injected in splitless mode and the oven temperature is programmed as follows: 50 °C for 5 min., increasing to 280 °C
(23°C/min) and holding for 10 rπin. The TSQ 700 spectrometer operates in electron impact (El) or chemical ionization (CI/CH4) mode (mass range 33 - 800, scan time 1.00 sec). The source temperature is set at 150 °C.
Specific rotation is recorded on a Perkin-Elmer 341 polarimeter. The angle of rotation is recorded at 25 °C on 1 % solutions in MeOH. For some molecules, the solvent is CH2CI2 or DMSO, due to solubility problems.
Melting points are determined on a Bύchi 535 or 545 Tottoli-type fusionometre, and are not corrected, or by the onset temperature on a Perkin Elmer DSC 7. Preparative chromatographic separations are performed on silicagel 60 Merck, particle size 15-40 μm, reference 1.15111.9025, using Novasep axial compression columns (80 mm i.d.), flow rates between 70 and 150 ml/min. Amount of silicagel and solvent mixtures as described in individual procedures.
Preparative Chiral Chromatographic separations are performed on a DAICEL Chiralpak AD 20 μm, 100*500 mm column using an in-house build instrument with various rnixtures of lower alcohols and C5 to C8 linear, branched or cyclic alkanes at ± 350 ml/min. Solvent mixtures as described in Individual procedures. The following abbreviations are used In the examples:
AcOEt Ethyl acetate
CH3CN Acetonitrile
DMF N,N-Dimethyfformamide
NBS N-brornosucclmmlde
NCS N-chlorosucc imide
NIS N-iodosucctøimide
TFA Trifluoroacetic acid
THF Tetrahydrofuran
In the tables, the stereochemical information is contained in the two columns headed "configuration". The second column indicates whether a compound has no stereogenic center (achiral), is a pure enantiomer (pure), a racemate (rac) or is a mixture of two stereoisomers, possibly in unequal proportions (MIXT). The first column contains the stereochemlcal assignment for the recognised center, following the IUPAC numbering used in the "IUPAC name" column. A number alone indicates the existence of both configurations at that center. A number followed by 'R' or 'S' indicates the known absolute configuration at that center. A number followed by '§' indicates the existence of only one but unknown absolute configuration at that center. The letter (A, B) in front is a way of distinguishing the various enantiomers of the same structure.
Example 1: Synthesis of 2-(5-iodo-2-oxo-2,3-dihydro-lH-mdol-l-yl)acetarnide 2.
Figure imgf000034_0001
2-(2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide l is synthesized according to the method described by Valenta et al. (Valenta, V.; Holubeck, J.; Svatek, E.; Valchar, M.; Krejci, I.; Protiva, M.; Collect. Czech. Chem. Commun. (1990), 55, 2756-2764).
Oxindole 1 (1 g, 5.25 rrrmol) was dissolved in CH3CN (20 ml). After addition of the NIS (1.3 g, 5.78 mmol), the TFA (217 μl, 1.57 mmol) was added and the reaction was allowed at room temperature for 16 h. After evaporation of the solvent, the rnixture was triturated in a 10 % aqueous solution of Na2S θ3. The beige solid formed was filtered, washed with water and with ether. After cristallization from 90 % aqueous EtOH, and re-cristallization from acetonitrile, 2-(5-iodo-2-oxo-2,3-dihydro- lH-indol-l-yl)acetamide 2 was obtained as a white solid.
Yield: 166 mg (10 %).
MS (GC-MS, M+-): 316.
Example 2: Synthesis of 2-(5-chloro-2-oxo-2,3-dihydro-lH-iιτdol-l-yl)acetamide 3.
Figure imgf000035_0001
Oxindole 1 (1.77 g, 9.3 mmol) was dissolved in 90 % H2SO (6 ml) at room temperature, and NCS (1.24 g, 9.3 mmol) was slowly added with stirring. After 2 hours, the rnixture was poured into cold water. The precipitate was collected, washed several times with water and then with Et2θ. After cristallization from EtOH, 2-(5- chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide 3 was obtained as a white solid. Yield: 479 mg (23 %). MS (LC-MS, MH+): 225/227.
MP: 226 °C.
Example 3: Synthesis of 2-(5,7-dibromo-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide 4.
Figure imgf000035_0002
2-(5,7-dibromo-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamlde 4 was obtained as described in example 1 by using 2 equivalents of NBS. The crude material was purified by silica gel chromatography. Yield: 129 mg (10 %).
MS (LC-MS, MH+): 259/261.
Example 4: Synthesis of 2-(5-nitro-2-oxo-2,3-d ydro-lH-indol-l-yl)acetamide 5.
Figure imgf000036_0001
To a stirred solution of 2-(2-oxo-2,3-dflιydro-lH- dol-l-yl)acetamide 1 (400 mg, 2.1 mmol) in TFA (20 ml) was added fuj iing nitric acid (170 μl, 2.7 mmol) over 10 minutes. Following addition, the ice bath was removed and the rnixture was stirred at room temperature for 5 minutes, then poured carefully into ice water. The precipitate was collected, washed with water until pH 7 and dried to give a crude solid. Cristallization in a mixture acetoriitrile/MeOH afforded the 2-(5-nitro-2-oxo-2,3- dihydro-lH-indol-l-yl)acetamide 5 as a green-gray solid. Yield: 150 mg (30 %).
MS (DIP, M+): 235.
Example 5: Synthesis of 2-(5-met yl-2-oxo-2,3-dihydro-lH-indol-l-yl)acetarnide 24.
Figure imgf000036_0002
5.1 Synthesis of 5'-methylspiro[ 1 ,3-dithlolane-2,3'-indol]-2'(l'H)-one 6.
5-methyl-lH-indole-2,3-dione (6 g, 37 mmol) was suspended in 100 ml of AcOH. The heterogenous mixture was heated at 60 °C. After complete solubilisation, 1,2-ethanedithiol (3.15 ml, 37 mmol) was added and then neat BF3.0Et2 (9.5 ml, 75 mmol) was added dropwise. The reaction was stirred for 25 minutes, in which time the reaction rnixture became homogenous. After 20 minutes at room temperature, the reaction was quenched by addition of water, the solid washed several times with large amounts of water and air dried affording 5'-methylspiro[l,3-dithiolane-2,3'-indol]- 2'(l'H)-one 6 as a brown solid. Yield: 8.65 g ( 98 %). MS (DIP, M+): 237. Compounds listed in table 1 can be synthesised according to the same method. Table 1
Figure imgf000037_0001
5.2 Synthesis of 2-[5'-methyl-2'-oxospiro[l,3-dithiolane-2,3'-indol]-l'(2'H)- yl]acetamide 15.
Compound 6 (8 g, 33.7 mmol) was dissolved in dry DMF (80 ml) under a nitrogen atmosphere. The solution was cooled at 0 °C and NaH (1.62 g, 37.13 mmol, 60 % dispersion) was carrefully added portionwise. When the nitrogen evolution ceased, bromoacetamlde (5.6 g, 37.13 mmol) was added. After 30 minutes, the mixture was poured into cold water and the solid filtered off, washed with water and hexane. The crude material was directly cristallized in acetonitrile affording 2-[5'- methyl-2'-oxospfro[l,3-ditMolane-2,3'-indol]-l'(2'H)-yl]acetamlde 15 as a white solid. Yield: 4.86 g (49 %). MS (LC-MS, MH+): 295.
Compounds listed in table 2 can be synthesised according to the same method.
Table 2:
No IUPAC NAME
15 2-(5 -m.etnyl-2'-oxospfro[l,3-di'l±ιiolane-2,3'-indol]-l'(2Η)-yl)acetamide
16 2-[2 -oxo-5'-[(trifluoromethyl)oxy]spfro[l,3-dithiolane-2,3'-indol]-l'(2'H)- yljacetamide
17 2-[5 - ( 1 -methylethyl) -2' -oxospiro [ 1 , 3-dithiolane-2 , 3'-indol] - 1 ' (2 Η) -yljacetamide
18 2-(5 -ethyl-2' -oxospiro [1,3 -dithiolane-2 , 3' -indol]- 1 ' (2'H) -yl) acetamide
19 2-(5 -fluoro-2'-oxospfro[l,3-dithiolane-2,3'-indol]-l'(2Η)-yl)acetamide
20 2-(5' ,7'-djjnethyl-2'-oxospfro[l,3-ditniolane-2,3'-mdol]-i 2Η)-yl)acetamide
21 2-(2 -oxo-5'-propylspiro[l,3-dithiolane-2,3'-indol]-l,(2'H)-yl)acetarnide
22 2-[2 -oxo-5'-(trifluoroιnethyl)spiro[l,3-dithiolane-2,3'-indol]-l,(2Η)-yl]acetajrιlde
23 2-(5 ,6'-dijmethyl-2'-oxospiro[l,3-ditlτiolane-2,3'-indol]-l'(2Η)-yl)acetaιrιide
5.3 Synthesis of 2-(5-methyl-2-oxo-2,3-dihydro-lH-indol-l-yl)acetarnide 24.
The Raney Nickel was prepared as an aqueous slurry after removing four fifth of water of the commercial solution. Aqueous Raney nickel (10 ml) was added to a solution of compound 15 (4.06 g, 13.8 mmol) in 40 ml of distilled THF and the mixture was further vigourously stirred at room temperature. When no starting material was detected by thin layer chromatography, the mixture was diluted with THF and filtered through a Celite pad. After removal of the solvent, the crude material was purified by silica gel chromatography (CH2Cl2/MeOH 95/5 then 90/10), and the solvent was evaporated to yield the 2-(5-methyl-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide 24 as a white solid.
Yield: 697 mg (21 %).
MS (LC-MS, MH+): 205.
Example 6: Synthesis of 2-(5-cMoro-2-oxo-2,3-d ydro-lH-indol-l-yl)propanamide 32, 33 and 34.
Figure imgf000039_0001
6.1 Synthesis of 2- (5-chloro- lH-indol-l-yl)propanamide 25.
A dispersion of 60 % NaH (6.85 g, 0.17 mol) was added to an ice-cooled solution of 5-chloroindole (20 g, 0.13 mol) In 250 ml of dry DMF. The stirring was continued for 20 minutes at room temperature, and the mixture was cooled again with an ice bath. After portlonwise addition of solid 2-bromopropanamide (24.1 g, 0.15 mol), the reaction rrjixture was stirred for lh30 at room temperature, then poured into cold water and extracted 3 times with AcOEt. The combined organic phases were dried over Na2Sθ4, filtered and concentrated in vacuo. The crude material was purified by silica gel chromatography (AcOEt/hexane 50/50) to give pure 2-(5-chloro-lH-indol-l- yUpropanamide 25 as a white solid.
Yield: 13.45 g (46 %).
MS (LC-MS, MH+): 223/225.
Compounds listed in table 3 can be synthesised according to the same method.
Table 3:
Figure imgf000040_0001
6.2 Synthesis of 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- 1 -yUpropanamide 32. Pyridinium bromide perbromide (38.8 g, 117 mmol) was added in portions over a period of 30 rninutes to a stirred solution of 2-(5-chloro-lf -indol-l-yl)propanamide 25 (13 g, 58.4 mmol) in ter -butanol (100 ml) at room temperature. The reaction mixture was stirred for 30 minutes, then poured into water and diluted with AcOEt. After removal of the organic layer, the aqueous phase was extracted twice with AcOEt. Combined organic phases were dried over Na2S04 and concentrated. 2-(3,3-dibromo- 5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)propanamide 31 was obtained as a crude oil and was directly used in the next step, without further purification.
Zinc dust (23.71 g, 0.58 mol) was added to a stirred solution of compound 31 (theorical: 58.4 mmol) in AcOH (110 ml) at 0 °C. After 1 hour, the reaction mixture was filtered through a Celite pad. The filtrate was diluted with AcOEt and cold water. The pH was adjusted to 7 and the layers were separated. The aqueous phase was extracted again with AcOEt. Organic layers were dried over Na2Sθ4 and concentrated. The beige solid was cristallized in AcOEt and afforded 2-(5-chloro-2-oxo-2,3-dihydro- lH-indol-1 -yUpropanamide 32 as a white solid. Yield: 2.5 g (18 %).
MS (LC-MS, MH+): 239/241.
Compound 32 (2.5 g, 10.5 mmol) was resolved into its enantiomers by chiral chromatography (DAICEL, Chiralcel OD phase, eluent : 50/50 ethanol/hexane) to afford enantiomers 33 (first eluted) and 34 (second eluted) as white solids. Compound 33:
Yield: 977 mg (39 %). MS (LC-MS, MH+): 239/241. MP: 171-172 °C. Compound 34:
Yield: 941 mg (37 %). MS (LC-MS, MH+): 239/241.
MP: 171-172 °C.
Example 7: Synthesis of N-(4-tert-Butyl-phenyl)-2-(5-chIoro-2-oxo-2,3-dihydro-indol- 1-yl) -acetamide 85.
Figure imgf000041_0001
7.1 Synthesis of ethyl (5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetate 58.
The ester 58 was obtained from 5-chloroindole and ethyl bromoacetate (instead of bromo-acetamide) using the methodology described in example 6.
MS (GC-MS, M+-): 253/255.
7.2 Synthesis of (5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetic acid 59.
In a two neck flask, ethyl (5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetate 58 (0.1 g, 0.39 mmol) was stirred overnight at room temperature in aqueous HCl (6 M, 2 ml) and warmed at 80 °C until disappearance of the starting material by TLC. The reaction mixture was cooled down to room temperature, filtered and the filtrate was washed by cold water to afford (5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetic acid 59 (74 mg).
LC/MS : 225/227 (MH+).
7.3 Synthesis of N-(4-tert-Butyl-phenyl)-2-(5-chloro-2-oxo-2,3-dihydro-indol-l-yl)- acetamide 85.
In a 1 ml polypropylene vial, 300 μl of a 0.15 M stock solution of (5-chloro-2- oxo-2,3-dihydro-lH-rndol-l-yl)acetic acid 59 in a 1/1 CH2CI2/DMF mixture were added onto N-dicyclohexyl-N'-methyl polystyrene (from Novabiochem, loading: 1.9 mmol/g, 35 mg) and N,N-diisopropyl-methyl-polystyrene (from Argonaut, loading: 3.49 mmol/g, 25.4 mg) followed by 4-tertbutyl~aniline (0.044 mmol, 6.6 mg). The reaction mixture was stirred 40 h under vortex and quenched with DMF (400 μl). The suspension was allowed to sediment and the liquid was concentrated under vacuo to afford N-(4-tert-butyl-phenyl)-2-(5-cMoro-2-oxo-2,3-dihydro-mdoI-l-yl)-acetarnlde 85 (10 mg).
MS (LC-MS, MH+): 357/359.
Compounds described in table 4 may be prepared according to one of the previous methods.
The synthesis intermediate 2-(7-fluoro-2-oxo-2, 3-dihydro- lH-indol-1- yUacetamide may also be prepared according to one of the previous methods.
Table 4: Compounds of formula I.
t
Figure imgf000043_0001
Figure imgf000044_0001
O
Figure imgf000044_0002
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000046_0002
Figure imgf000046_0003
Figure imgf000047_0001
Figure imgf000047_0002
Figure imgf000048_0001
l
Figure imgf000048_0002
Figure imgf000049_0001
Figure imgf000049_0002
00
Example 8: LBS Binding Assay.
[LBS stands for Levetiracetam Binding Site cf. M. Noyer et al., Eur. J. Pharmacol. (1995), 286, 137-146.]
The inhibition constant (Kt) of a compound is determined in competitive binding experiments by measuring the binding of a single concentration of a radioactive ligand at equilibrium with various concentrations of the unlabeled test substance. The concentration of the test substance inhibiting 50 % of the specific binding of the radioligand is called the IC50. The equilibrium dissociation constant Kj is proportional to the IC5Q and is calculated using the equation of Cheng and Prusoff (Cheng Y. et al., Biochem. Pharmacol. (1972), 22, 3099-3108).
The concentration range usually encompasses 6 log units with variable steps (0.3 to 0.5 log). Assays are performed in mono- or duplicate, each Ki determination is performed on two different samples of test substance.
Cerebral cortex from 200-250 g male Sprague-Dawley rats are homogenised using a Potter S homogeniser (10 strokes at 1,000 rpm; Braun, Germany) in 20 mmol/1 Tris-HCl (pH 7.4), 250 rnmol/1 sucrose (buffer A); all operations are performed at 4 °C. The homogenate is centrifuged at 30,000xg for 15 min. The crude membrane pellet obtained is resuspended in 50 mmol/1 Tris-HCl (pH 7.4), (buffer B) and incubated 15 rnln at 37 °C, centrifuged at 30,000xg for 15 min and washed twice with the same buffer. The final pellet is resuspended in buffer A at a protein concentration ranging from 15 to 25 mg/ml and stored in liquid nitrogen.
Membranes (150-200 μg of protein / assay) are incubated at 4 °C for 120 min in 0.5 ml of a 50 mmol/1 Tris-HCl buffer (pH 7.4) containing 2 mmol/1 MgCl2 , 10~9 to 2.10~9 mol/1 of [3H]-2-[4-(3-azidophenyl)-2-oxo- l-pyrrolidinyl]butanamlde and increasing concentrations of the test substance. The non specific binding (NSB) is defined as the residual binding observed in the presence of a concentration of reference substance (e.g. 10"3 mol/1 levetiracetam) that binds essentially all the receptors. Membrane-bound and free radioligands are separated by rapid filtration through glass fiber filters (equivalent to Whatman GF/C or GF/B; VEL, Belgium) pre- soaked in 0.1 % polyethyleneirnine and 10"3 mol/1 levetiracetam to reduce non specific binding. Samples and filters are rinsed by at least 6 ml of 50 mmol/1 Tris-HCl (pH 7.4) buffer. The entire filtration procedure does not exceed 10 seconds per sample. The radioactivity trapped onto the filters is counted by liquid scintillation in a β- counter (Tri-Carb 1900 or TopCount 9206, Camberra Packard, Belgium, or any other equivalent counter). Data analysis is performed by a computerized non linear curve fitting method using a set of equations describing several binding models assuming populations of independent non-interacting receptors, which obey to the law of mass. Example 9: Ariimal model of sound-susceptible mice.
The aim of this test is to evaluate the anticonvulsant potency of a compound in sound-susceptible mice, a genetic animal model with reflex seizures. In this model of primary generalised epilepsy, seizures are evoked without electrical or chemical stimulation and the seizure types are, at least in part, similar in their clinical phenomenology to seizures occurring in man (Lδscher W. & Schmidt D., Epilepsy Res. (1998), 2, 145-181; Buchhalter J.R., Epilepsia (1993), 34, S31-S41).
Male or female genetically sound-sensitive mice (14-28 g; N=10), derived from a DBA strain originally selected by Dr. Lehmann of the Laboratory of Acoustic
Physiology (Paris) and bred in the UCB Pharma Sector husbandry unit since 1978, are used. The experimental design consists of several groups, one group receiving the vehicle control and the other groups different doses of the test-compound. The compounds are adrrrlnlstered intraperitoneally 60 rninutes before the induction of audiogenic seizures. The range of the doses adrnirtistered has a logarithmic progression, generally between 1.0 x 10"^mol/kg and 1.0 x 10- mol/kg, but lower or higher doses are tested if necessary.
For testing, the animals are placed in small cages, one mouse per cage, in a sound-attenuated chamber. After a period of orientation of 30 seconds, the acoustic stimulus (90 dB, 10-20 kHz) is delivered for 30 seconds via loudspeakers positioned above each cage. During this interval, the mice are observed and the presence of the 3 phases of the seizure activity namely wild running, clonic and tonic convulsions, is recorded. The proportion of mice protected against wild running, clonic and tonic convulsions, respectively, is calculated. For active compounds, an ED50 value, i.e. the dose producing 50 % protection relative to the control group, together with 95 % confidence limits, was calculated using a Probit Analysis (SAS/STAT® Software, version 6.09, PROBIT procedure) of the proportions of protected mice for each of the 3 phases of the seizure activity.

Claims

Claims
1. A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
Figure imgf000052_0001
wherein
R! is hydrogen,
R2 is hydrogen or Cl-20-alkyl,
R3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R3.
R3a is hydrogen, Cl-20-alkyl or a group of formula:
Figure imgf000052_0002
or NR3R3a is a group of formula
Figure imgf000052_0003
R4 is hydrogen,
R5 is hydrogen; nitro; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl;
-Sθ2-Cl-4-alkyl; -SONH2; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen,
R6 is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, Cl-20-alkyl or halogen,
W is Cl-12-alkylene, -NH- or -NHC(=0)-,
X is O, S or NH,
Y is O, S, -CR12R13-, -NR14- or -C(=0)-,
R^ is aryl or heterocycle,
R9, R1 J RlOa ajjfj R11 gj-g independently selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or RIO and RlOa together form a C3-6-alkylene,
R^2 is hydrogen, Cl-4-alkyl, halogen or hydroxy,
RI is hydrogen, or CR12R13 is dioxolanyl,
R1 is aryl, heterocycle or a group of formula -V-R-Α
V is Cl-12-alkylene, pi 5 iS aryl or heterocycle, m is 1 to 4, n is 0 or 1 , and at least one of Rβ, β or R7 is different from hydrogen when R2 is hydrogen,
R3 is H or 2,6-diisopropylphenyl, and R3a is H.
A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
Figure imgf000053_0001
wherein
R! is hydrogen,
R2 is hydrogen or Cl-4-alkyl,
R3 is hydrogen; Cl-6-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl or alkylamino; C5-7- cycloalkyl; (hydroxymethyUcyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, Cl-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl, trifluorornethylthio or pyridinylalkyl; pyridinyl unsubstituted or substituted by methoxy; triazolyl; Cl-4-alkoxy; or a group of formula -W-R^,
R a is hydrogen, Cl-4-alkyl or a group of formula
Figure imgf000053_0002
or NR3R a is piperidinyl unsubstituted or substituted by hydroxy; thiomorpholinyl; thiazolidinyl unsubstituted or substituted by Cl-4- alkoxycarbonyl; 2,5-dihydro-lH-pyrrol-l-yl; l,4-dioxa-8-azaspiro[4.5]dec-8-yl; 4- oxooctahydro-l(2H)-quinolinyl; or a group of formula
/ \ 14
N 1 N—
\ /
R4 is hydrogen, Rβ is hydrogen; nitro; halogen; Cl-4-alkyl, unsubstituted or substituted by halogen; or Cl-4-alkoxy unsubstituted or substituted by halogen,
R6 is hydrogen, Cl-6-alkyl or halogen,
R7 is hydrogen, methyl or halogen,
W is Cl-4-alkylene unsubstituted or substituted by halogen, hydroxy, Cl-4-alkyl or alkoxy; -NH-; or -NHC(=0)-,
Rβ is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, Cl-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluorornethylthio; furyl unsubstituted or substituted by methyl; pyrazolyl; pyridinyl; morpholinyl; tetrahydrobenzazocinyl; piperidinyl unsubstituted or substituted by methyl; dihydroisochromenyl or dihydroimidazolyl,
R^ is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, Cl-4- alkyl; or a group of formula -V-R-Α
V is unsubstituted Cl-4-alkylene,
Rl5 is phenyl or morpholinyl, m is 1 to 4, and at least one of R^, R^ or R7 is different from hydrogen when R2 is hydrogen,
R3 is H or 2,6-diisopropylphenyl, and R3a is H.
A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,
Figure imgf000054_0001
wherein
R! is hydrogen,
R2 is hydrogen, methyl or ethyl,
R3 is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3-hydroxypropyl, 3-hydroxy-
2,2-dlmethylpropyl, l-(hydroxymethyl)propyl, 3,3)3-trifluoro-2-hydroxypropyl, 3- ethoxypropyl, 2-ethoxy-2-oxoethyl, 3-(dirnethylamino)propyl, 6-
(hydroxymethyl)cyclohex-3-en-l-yl, 3-hydroxyphenyl, 3 -fluorophenyl, 3-(2-pyridin-
2-ylethyl)phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3- methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 2-chloro-6-fluorobenzyl, 2-
[(trifluoromethyl)ttao]benzyl, 2-hydroxy-2-phenylethyl, 2-(3,4- dimethoxyphenyUethyl, 2-(2-chlorophenyl)ethyl, 2-(4-methylphenyl)ethyl, (4- brornophenyUamino, pyridin-3-yl, 6-methoxypyridin-3-yl, 4H-l,2,4-triazol-3-yl, pyridin-4-ylmethyl, (5-methyl-2-ιuryl)methyl, 3-(lH-pyrazol-l-yl)propyl, 2- morpholin-4-ylethyl, 2-((3,4,5,6-tetrahydro-l-benzazocin-l(2H)-yl)propyl, 2-(2- methylpiperidin-l-yl)ethyl, 3,4-dihydro-lH-isochromen-l-ylmetlιyl, methoxy, (4- pyιidinylcarbonyl)arnino or 4,5-dflιydro-lH-lmldazol-2-ylarnino,
R3a is hydrogen, methyl or tetrahydrofuran-2-ylmethyl, or NR R a 4-pyridin-2-ylpiperazin-l-yl, 4-(3-methylphenyl)piperazin-l-yl, 4-(4- hydroxyphenyl)piperazin-l-yl, 4-(2-phenylethyl)piperazin-l-yl, 4-(2-morpholin-4- ylethyUpiperazfn-1-yl, 3-hydroxypiperidin-l-yl, thiomorpholin-4-yl, 4- methoxycarbonyl-1 ,3-thiazolidin-3-yl, 2, 5-dihydro- lH-pyrrol- 1-yl, 1 ,4-dioxa-8- azaspiro[4.5]dec-8-yl or 4-oxooctahydro-l(2H)-quinolinyl,
R4 is hydrogen,
Rβ is hydrogen, methyl, ethyl, trifluoromethyl, trifluoromethoxy, n-propyl, isopropyl, nitro or halogen,
R^ is hydrogen, methyl or CI,
R7 is hydrogen, methyl, Br, F or CI, and at least one of R^, β or R7 is different from hydrogen when R2 is hydrogen,
R3 is H or 2,6-diisopropylphenyl, and R3a is H.
4. A compound according to any of the claims 1 to 3 wherein R2 is hydrogen or methyl.
5. A compound according to any of the preceding claims wherein R3 is hydrogen.
6. A compound according to any of the preceding claims wherein R a is hydrogen.
7. A compound according to any of the preceding claims wherein R^ is halogen or trifluoromethyl.
8. A compound according to any of the preceding claims wherein R^ is hydrogen.
9. A compound according to any of the preceding claims wherein R7 is hydrogen, Br or F.
10. A compound according to any of the preceding claims wherein R2 is Cl-20-alkyl and the carbon atom to which R2 is attached is in the "S"-configuration.
1. A compound selected from 2-(5-iodo-2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide; 2- (5-chloro-2-oxo-2, 3-dihydro- lH-indol- 1-yl) acetamide; 2-(5,7-dibromo-2-oxo-2,3- dihydro-lH-indol-l-yl)acetamide; 2-(5-nitro-2-oxo-2, 3-dihydro- lH-indol-1- yUaeetamide; 2-(5-ιnetnyl-2-oxo-2,3-dihydro-lH-mdol-l-yUacetarjaide; 2-(5-chloro-
2-oxo-2,3-djjιydro-lH-jndol-l-yl)propanarnide; (2R)-2-(5-chloro-2-oxo-2,3-dihydro- lH-indol-1-yUpropanamlde; (2S)-2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l- yUpropanamide; 2-[2-oxo-5-(ixifluorornethoxy)-2,3-dihydro-lH-indol-l- yUacetamide; 2-(5-isopropyl-2-oxo-2, 3-dihydro- lH-indol- l-yl)acetamide; 2-(5-ethyl- 2-oxo-2,3-dihydro-lH-indol-l-yl)acetamide; 2-(5-fluoro-2-oxo-2, 3-dihydro- 1H- indol- 1-yl) acetamide; 2-(5,7-dimethyl-2-oxo-2>3-dihydro-lH-indol-l-yl)acetamide; 2-(5-bromo-2-oxo-2, 3-dihydro- lH-indol- 1 -yUaeetamide; 2-(2-oxo-5-propyl-2,3- dihydro-lH-indol-l-yl)acetamide; 2-[2-oxo-5-(trifluoromethyl)-2,3-dihydro-lH- indol- 1-yl] acetamide; 2-(5,6-dimethyl-2-oxo-2,3-dihydro-lH-indol-l-yUacetaιnide; 2-(7-chloro-2-oxo-2,3-dihydro-lH-indol-l-yUacetamide; 2-(6-chloro-2-oxo-2,3- dihydro-lH-indol-l-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l- yUbutanamlde; (+)-2-(5-cMoro-2-oxo-2,3-dmydro-lH-indol-l-yl)butanarnide; (-)-2- (5-chloro-2-oxo-2, 3-dihydro- lH-indol-l-yUbutanarnide; 2-(5-methyl-2-oxo-2,3- dihydro-lH-indol-1 -yUpropanamide; (+)-2-(5-methyl-2-oxo-2,3-dihydro-lH-indol-l- yUpropanamide; (-)-2-(5-metnyl-2-oxo-2,3-dflιydro-lH-indol-l-yl)propanarnide; 2-
(5-bromo-2-oxo-2,3-dihydro- lH-indol- l-yl)propanamide; (-)-2-(5-bromo-2-oxo-2,3- dihydro-lH-indol-1 -yUpropanamide; (+)-2-(5-bromo-2-oxo-2,3-dihydro-lH-indol-l- yUpropanamlde; 2-(5-chloro-7-fluoro-2-oxo-2, 3-dihydro- lH-indol- l-yl)acetamide; 2-(5-cMoro-2-oxo-2,3-djjιydro-lH-indol-l-yl)-N-(3-hydroxyphenyl)acetarnlde; 2-(5- chloro-2-oxo-2 , 3-dihydro- 1 H-indol- 1 -yl) -N-(3-fluorophenyl) acetamide ; 2- (5-chloro-
2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[3-(2-pyridin-2-ylethyl)phenyl]acetamlde; 2-(5- chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-l- yl]acetamide; 5-chloro-l-[2-oxo-2-(4-pyridin-2-ylpiperazin-l-yl)ethyl]-l,3-dihydro- 2H-indol-2-one; 5-chloro-l-{2-[4-(3-methylphenyl)piperazin-l-yl]-2-oxoethyl}-l,3- dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-(4- hydroxy-3-methoxybenzyl) acetamide; 2- (5-chloro-2-oxo-2 , 3-dihydro- 1 H-indol- 1 -yl) - N-(pyridin-4-ylmethyU-N-(tetrahydrofuran-2-yj nethyl)acetarrιide; 5-chloro- 1 -[2-(3- hydroxypiperidin- l-yl)-2-oxoethyl]- 1 ,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo- 2,3-dihydro-lH-indol-l-yl)-N'-isonicotlnoylacetohydrazide; 5-chloro-l-(2-oxo-2- thiornorpholin-4-ylethyl)- 1 ,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3- dihydro-lH-indol-l-yl)-N-(4H-l,2,4-1riazol-3-yl)acetamide; 2-(5-chloro-2-oxo-2,3- dlhydro-lH-indol-l-yl)-N-[4-(methylsuffonyl)benzyl]acetamide; l-[(5-chloro-2-oxo- 2,3-dmydro-lH- dol-l-yUacetyl]octahydroqufnolin-4(lH)-one; N'-(4-bromophenyl)- 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol-l-yl)acetohydrazide; 2-(5-chloro-2-oxo-2,3- d ydro-lH-lndol-l-yl)-N-(6-methoxypyridln-3-yl)acetarnide; N-butyl-2-(5-chloro-2- oxo-2,3-dihydro-lH-indol-l-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol- l-yl)-N-(3-hydroxypropyl)acetarnide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-
N-[3-(dimethylamtao)propyl]acetarnide; 5-chloro- l-{2-oxo-2-[4-(2- phenyleth.yl)piperazin-l-yl]ethyl}-l,3-dihydro-2H-indol-2-one; ethyl {[(5-chloro-2- oxo-2, 3-dihydro- lH-indol- l-yl)acetyl]aιnino}acetate; 2-(5-chloro-2-oxo-2,3-dihydro- lH-indol-l-yU-N-(3-ethoxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH- indol- l-yl)-N-(2-fluoroethyl)acetarnide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- 1- yU-N-methoxy-N-methylacetamide; 2-(5-chloro-2-oxo-2)3-dihydro-lH-indol-l-yl)-N- (3,4-diιnethylphenyUacetarnide; N-(4-tert-butylphenyl)-2-(5-chloro-2-oxo-2,3- dihydro- lH-indol- 1 -yUaeetamide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol- 1 -yl)-N- (3-hydroxy-2,2-dimethylpropyl)acetørrιide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol- l-yl)-N-[l-(hydroxyιnethyl)propyl]acetaιnide; 2-(5-chloro-2-oxo-2,3-dihydro-lH- indol-l-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3- dihydro-lH-indol-l-yl)-N-(2-hydroxy-2-phenylethyUacetamide; 5-chloro- 1-{2-[4-(4- hydroxyphenyUpiperazin- l-yl]-2-oxoethyl}- 1 ,3-dihydro-2H-indol-2-one; 2-(5-chloro- 2-oxo-2,3-djjιydro-lH-indol-l-yl)-N-(pyridin-4-yJτnethyUacetamide; 2-(5-chloro-2- oxo-2,3-dihydro-lH-indol-l-yl)-N-[(5-methyl-2-j^ryl)methyl]acetarnlde; 2-(5-chloro-
2-oxo-2, 3-dihydro- lH-mdol-l-yl)-N-[3-(lH-pyrazol-l-yl)propyl]acetarrιide; methyl 3-[(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetyl]-l,3-thiazolidine-4-carboxylate; 5-chloro-l-[2-(2,5-dihydro-lH-pyrrol-l-yU-2-oxoethyl]-I,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N'-(4,5-dihydro-lH-imldazol-2- yUacetohydrazide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-[2-(3(4- diιnethoxyphenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N- [2-(2-chlorophenyUethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)- N-[2-(4-methylphenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol-1- yU-N-(2-morpholm-4-ylethyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l- yl)-N-[2-(3,4,5,6-tetrahydro-l-benzazocin-l(2H)-yUpropyl]acetarnlde; 2-(5-chloro-2- oxo-2,3-dflιydro-lH-indol-l-yU-N-[2-(2-methylpiperidin-l-yl)ethyl]acetamide; 2-(5- chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-(2-nitrobenzyUacetarnide; 2-(5-chloro-2- oxo-2, 3-dihydro- lH-indol- 1 -yl)-N-(3,4-dihydro- lH-isochromen- 1- ylmethyUacetamlde; N-(2-chloro-6-fluorobenzyl)-2-(5-chloro-2-oxo-2,3-dihydro-lH- indol- l-yl)acetamide; N-benzyl-2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N- methylacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)-N-{2- [(trifluoromemyl)thio]benzyl}acetamide; 5-chloro-l-[2-(l,4-dioxa-8- azasp o[4.5]dec-8-yl)-2-oxoethyl]-l,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo- 2,3-djJiydro-lH-jndol-l-yl)-N-cycloheptylacetarnide; 5-chloro- l-{2-[4-(2-morpholin- 4-ylethyl)piperazin-l-yl]-2-oxoethyl}-l,3-dihydro-2H-indol-2-one; and 2-(5-chloro- 2-oxo-2,3-dmydro-lH-indol-l-yU-N-pyridin-3-ylacetamide.
12. A compound selected from 2-(5-chloro-2-oxo-2, 3-dihydro- lH-indol-1 -yUaeetamide and (2S)-2-(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)propanarnide.
13. A compound having the formula II or stereoisomeric forms thereof,
Figure imgf000058_0001
wherein
Rl is hydrogen,
R2 is hydrogen or Cl-20-alkyl,
R3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R8.
R a is hydrogen, Cl-20-alkyl or a group of formula:
Figure imgf000058_0002
or NR3R3a is a group of formula
Figure imgf000058_0003
R4 is hydrogen,
Rβ is hydrogen; nitro; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl; -S02-Cl-4-alkyl; -SONH2; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen, R^ is hydrogen, Cl-20-alkyl or halogen, R7 is hydrogen, Cl-20-alkyl or halogen, W is Cl-12-alkylene, -NH- or -NHC(=0)-, X is O, S or NH,
Y is O, S, -CR12R13-, -NR14- or -C(=0)-, β is aryl or heterocycle, 9> ρl05 plOa ajyj pll g^-g independenlty selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R10 and R10a together form a C3-6-alkylene, R12 is hydrogen, Cl-4-alkyl, halogen or hydroxy, R1 is hydrogen, or CR^2R^3 is dioxolanyl,
R1 is aryl, heterocycle or a group of formula -V-R-Α V is Cl-12-alkylene, R!5 is aryl or heterocycle, m is 1 to 4, n is 0 or 1, and at least one of Rβ, β or R7 is different from hydrogen when R2 is hydrogen, R3 is H or 2,6-diisopropylphenyl, and R3a is H.
14. A compound having the formula III or stereoisomeric forms thereof,
Figure imgf000059_0001
wherein R4 is hydrogen,
Rβ is hydrogen; nitro; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl; -S02-Cl-4-alkyl; -SONH2; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen, R6 is hydrogen, Cl-20-alkyl or halogen, R7 is hydrogen, Cl-20-alkyl or halogen, and at least one of Rβ, R or R7 is different from hydrogen.
15. A compound having the formula VI or stereoisomeric forms thereof,
Figure imgf000059_0002
wherein
R! is hydrogen, R2 is hydrogen or Cl-20-alkyl,
R3 is hydrogen, Cl-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, Cl-20-alkoxy, or a group of formula -W-R^. p3a s hydrogen, Cl-20-alkyl or a group of formula:
Figure imgf000060_0001
or NR3R3a is a group of formula:
Figure imgf000060_0002
R4 is hydrogen,
R5 is hydrogen; halogen; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl; -S02-Cl-4-alkyl; -SONH2; or Cl-20-alkyl unsubstituted or substituted by halogen, is hydrogen, Cl-20-alkyl or halogen,
R7 is hydrogen, C2-20-alkyl or halogen,
W is Cl-12-alkylene, -NH- or -NHC(=0)-, X is O, S or NH,
Y is O, S, -CR12R13-, -NR14- or -C(=0)-,
Rβ is aryl or heterocycle, 9; plOt RlOa a d R^ are Independenlty selected from hydrogen, Cl-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R1 ° and R10a together form a C3-6-alkylene,
R* is hydrogen, Cl-4-alkyl, halogen or hydroxy,
R*3 is hydrogen, or CR12R13 is dioxolanyl,
R*4 is aryl, heterocycle or a group of formula
Figure imgf000060_0003
V is Cl-12-alkylene,
R} is aryl or heterocycle, m is 1 to 4, n is 0 or 1, and at least one of Rβ, R^ or R7 is different from hydrogen when R2 is hydrogen, R3 is H or 2,6-diisopropylphenyl, and R a is H.
16. A compound having the formula IX or stereoisomeric forms thereof,
Figure imgf000061_0001
wherein R} is hydrogen, R2 is hydrogen or Cl-20-alkyl, R4 is hydrogen,
Rβ is hydrogen; nitro; azido; cyano; -S-Cl-4-alkyl; -SO-Cl-4-alkyl; -Sθ2-Cl-4-alkyl; -SONH ; halogen; Cl-20-alkyl unsubstituted or substituted by halogen; or Cl-20-alkoxy unsubstituted or substituted by halogen, R^ is hydrogen, Cl-20-alkyl or halogen, R7 is hydrogen, Cl-20-alkyl or halogen, and at least one of , R or R7 is different from hydrogen when R2 is hydrogen, R3 is H or 2,6-diisopropylphenyl, and R3a is H.
17. A compound which is selected from the group consisting of: 2-(5'-methyl-2'-oxospiro[l,3-dithiolane-2>3'-indol]-l'(2'H)-yl)acetamide;
2-[2'-oxo-5'-[(trifluoromethyl)oxy]spiro[ 1 ,3-dithiolane-2,3'-indol]- 1 '(2'H)- yl]acetamide;
2-[5'-(l-methylethyU-2'-oxospfro[l,3-dit olane-2,3'-indol]-l'(2'H)-yl]acetamide;
2-(5' -ethyl-2' -oxospiro! 1 , 3-dithiolane-2 , 3' -indol] - 1 ' (2'H) -yl) acetamide; 2-(5'-fluoro-2'-oxospfro[l,3-dithiolane-2,3'-indol]-l'(2Η)-yUacetarnide;
2-(5 7'-dimerιyl-2,-oxospiro[l,3-dithiolane-2,3'-mdoll-l'(2Η)-yl)acetamide; 2-(2'- oxo-5'-propylspfro[l,3-ditMolane-2,3,-indol]-l'(2Η)-yl)acetaπιide;
2-[2'-oxo-5'-(trifluoromethyl)spfro[l,3-dithiolane-2,3'-indol]-l'(2Η)-yl]acetanτide;
2-(5 6'-dimethyl-2'-o ospiro[l,3-dit iolane-2,3'-mdol]-l,(2^)-yl)acetamide; 5'-methylspiro[ 1 ,3-dithiolane-2,3'-indol]-2,(l,H)-one;
5'-[(tofluorome1±ιyl)oxy]spiro[l,3-dithiolane-2,3,-indol]-2'(lΗ)-one;
5'-(l-methylethyl)spfro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one;
5'-ethylspiro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one;
5' -fluorospiro [ 1 , 3-dithiolane-2 , 3'-indol] -2' ( 1 Η) -one; 5 7'-djjnethylspfro[l,3-dithiolane-2,3'-indol]-2'(l'H)-one;
5'-propylsp o[l,3-dithiolane-2,3'-indol]-2'(lΗ)-one;
5'-(trτluoromethyUspfro[l,3-dithiolane-2,3'-indol]-2'(lΗ)-one;
5 6'-dimet yls Jro[l,3-diτhiola e-2,3,-i dol]-2,(l^)-one; 2-(5-chloro-lH-indol-l-yl)propanamide; 2-(7-chloro- lH-indol- l-yl)acetamide; 2-(6-chloro- lH-indol- 1 -yUaeetamide; 2-(5-chloro-lH-indol-l-yl)butanamlde; 2-(5-methyl- lH-indol- 1-yUpropanamide;
2-(5-bromo- lH-indol- 1 -yUpropanamide; 2-(7-fluoro- lH-indol- 1 -yUaeetamide; 2-(5-bromo- lH-indol- l-yl)acetamide; 2-(5-fluoro-lH-indol-l-yl)acetaιnide; 2-(5-chloro- lH-indol- 1 -yUaeetamide;
(5-chloro-2-oxo-2,3-dihydro-lH-indol-l-yl)acetic acid.
18. A pharmaceutical composition comprising an effective amount of a compound according to any of claims 1 to 12 in combination with a pharmaceutically acceptable diluent or carrier.
19. A method for treating epilepsy, epileptogenesis, seizure disorders, convulsions, Parkinson's disease, dyskinesia induced by dopamine replacement therapy, tardlve dyskinesia induced by administration of neuroleptic drugs, Huntington Chorea, and other neurological disorders including bipolar disorders, mania, depression, anxiety, attention deficit hyperactivlty disorder (ADHD), migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, ***e abuse, stroke, myoclonus, tremor, essential tremor, simple or complex tics, Tourette syndrome, restless leg syndrome and other movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis, in a mammal in need of such treatment, comprising administering a therapeutic dose of at least one compound according to any of claims 1-12 or a pharmaceutical composition according to claim 18.
20. A compound according to any of claims 1-12 or a pharmaceutical composition according to claim 18 for use as a medicament.
21. Use of a compound according to any of claims 1-12 or of a pharmaceutical composition according to claim 18 for the manufacture of a medicament for the treatment of epilepsy, epfleptogenesis, seizure disorders, convulsions, Parkinson's disease, dyskinesia induced by dopamine replacement therapy, tardive dyskinesia induced by adininistration of neuroleptic drugs, Huntington Chorea, and other neurological disorders including bipolar disorders, mania, depression, anxiety, attention deficit hyperactMty disorder (ADHD), migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, ***e abuse, stroke, myoclonus, tremor, essential tremor, simple or complex tics, Tourette syndrome, restless leg syndrome and other movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctMtis.
PCT/EP2004/002691 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses WO2004087658A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AT04720863T ATE482193T1 (en) 2003-03-31 2004-03-16 INDOLONEACETAMIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USES
MXPA05009089A MXPA05009089A (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses.
DE602004029245T DE602004029245D1 (en) 2003-03-31 2004-03-16 INDOLONACETAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ITS USE
EP04720863A EP1620399B1 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses
JP2006504696A JP2006522041A (en) 2003-03-31 2004-03-16 INDORONACETAMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
CA002520568A CA2520568A1 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses
AU2004226288A AU2004226288A1 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses
US10/550,667 US7645887B2 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses
BRPI0408863-8A BRPI0408863A (en) 2003-03-31 2004-03-16 compound, pharmaceutical composition, method for treating diseases, and use of a compound.
NO20055026A NO20055026L (en) 2003-03-31 2005-10-28 Indolone acetamide derivatives, processes for their preparation and use
HK06110230A HK1089768A1 (en) 2003-03-31 2006-09-15 Indolone-acetamide derivatives, processes for preparing them and their uses
US12/622,533 US7964593B2 (en) 2003-03-31 2009-11-20 Indolone-acetamide derivatives, processes for preparing them and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03007214.4 2003-03-31
EP03007214 2003-03-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/550,667 A-371-Of-International US7645887B2 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses
US12/622,533 Division US7964593B2 (en) 2003-03-31 2009-11-20 Indolone-acetamide derivatives, processes for preparing them and their uses

Publications (1)

Publication Number Publication Date
WO2004087658A1 true WO2004087658A1 (en) 2004-10-14

Family

ID=33104041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002691 WO2004087658A1 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses

Country Status (19)

Country Link
US (2) US7645887B2 (en)
EP (1) EP1620399B1 (en)
JP (1) JP2006522041A (en)
KR (1) KR20050119186A (en)
CN (1) CN100364973C (en)
AR (1) AR043959A1 (en)
AT (1) ATE482193T1 (en)
AU (1) AU2004226288A1 (en)
BR (1) BRPI0408863A (en)
CA (1) CA2520568A1 (en)
DE (1) DE602004029245D1 (en)
ES (1) ES2353461T3 (en)
HK (1) HK1089768A1 (en)
MX (1) MXPA05009089A (en)
NO (1) NO20055026L (en)
RU (1) RU2005131317A (en)
TW (1) TW200508197A (en)
WO (1) WO2004087658A1 (en)
ZA (1) ZA200507231B (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080334A1 (en) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
WO2006008067A1 (en) * 2004-07-22 2006-01-26 Ucb, S.A. Indolone derivatives, processes for preparing them and their uses
WO2006128693A3 (en) * 2005-06-01 2007-04-19 Ucb Pharma Sa 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
EP1931348A2 (en) * 2005-08-16 2008-06-18 ChemoCentryx Inc Monocyclic and bicyclic compounds and methods of use
WO2008132142A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US7645887B2 (en) 2003-03-31 2010-01-12 Ucb Pharma, S.A. Indolone-acetamide derivatives, processes for preparing them and their uses
US7868181B2 (en) 2006-02-07 2011-01-11 Astrazeneca Ab Compounds
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
KR101213345B1 (en) 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 Composition containing anti-dementia drug
US8604075B2 (en) 2008-10-16 2013-12-10 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN107540597A (en) * 2017-09-22 2018-01-05 苏州大学 The preparation method of the ketone derivatives of N dimethylacetamide bases indoles 2
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2019232083A1 (en) * 2018-05-29 2019-12-05 New York University Compounds and methods for treating bacterial infections
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
KR102669101B1 (en) 2021-08-10 2024-05-27 충북대학교 산학협력단 A novel oxoindoline-based acetohydrazide and an anticancer composition comprising the same as an active ingredient

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120729A2 (en) 2006-04-12 2007-10-25 Merck & Co., Inc. Pyridyl amide t-type calcium channel antagonists
WO2008133933A1 (en) * 2007-04-26 2008-11-06 Trustees Of Columbia University In The City Of New York Methods, systems, and compositions for treating or ameliorating the effects of a non-congenital hypertonia
AU2008317353B2 (en) * 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
JP2011500808A (en) * 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション Heterocyclic amide T-type calcium channel antagonist
CN114874127B (en) * 2022-05-23 2023-06-09 中国药科大学 Preparation method of difluoro carbonyl indolone compound

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022317A1 (en) * 1979-06-12 1981-01-14 Fujisawa Pharmaceutical Co., Ltd. 2-Oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives
US4624963A (en) * 1984-04-11 1986-11-25 Hoechst Aktiengesellschaft Use of oxindole compounds for the treatment of epilepsy
EP0445781A1 (en) * 1990-03-08 1991-09-11 Sterling Winthrop Inc. 3-Arylcarbonyl-1-aminoalkyl-1H-indole containing antiglaucoma compositions
WO1994029272A1 (en) * 1993-06-16 1994-12-22 Astra Aktiebolag 1-substituted isatin and oxindole derivatives as inhibitors of acetylcholinesterase
WO1998001428A1 (en) * 1996-07-08 1998-01-15 Du Pont Pharmaceuticals Company AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN
JPH1095766A (en) * 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd Acetamide derivative and its use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5697268A (en) * 1979-12-28 1981-08-05 Fujisawa Pharmaceut Co Ltd Lower alkanoic acid derivative, salt and preparation thereof and preventing agent and remedy for diabetic complication containing the same as active constituent
SU841264A1 (en) * 1980-02-20 1995-11-10 Научно-исследовательский институт фармакологии АМН СССР Amide-2-oxo-1-indolineacetic acid possessing anticonvulsive activity
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
DK288287A (en) * 1986-06-09 1987-12-10 Pfizer HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL PREPARATIONS FOR TREATMENT OF ALLERGIC OR INFLAMMATORY CONDITIONS
JPH0195766A (en) 1987-10-08 1989-04-13 Tamanoisu Kk Preparation of food vinegar from uncooked unrefined alcohol
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
BR9200951A (en) * 1991-03-21 1992-11-17 Hoffmann La Roche COMPOUNDS, PROCESS FOR ITS PRODUCTION, PHARMACEUTICAL PREPARATIONS AND USE
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5514690A (en) 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
JPH07304736A (en) * 1994-05-10 1995-11-21 Kyowa Hakko Kogyo Co Ltd Indole derivative
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
FR2738818B1 (en) * 1995-09-18 1997-12-05 Valentonine NOVEL OXIDATION DERIVATIVES OF INDOLYLALKYLAMINES AND THEIR USE AS MEDICAMENTS
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
AU2002213204A1 (en) * 2000-10-13 2002-04-22 Bristol-Myers Squibb Company Selective maxi-K- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
DE602004013563D1 (en) * 2003-03-14 2008-06-19 Merck & Co Inc RANTAGONISTEN
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
ATE482194T1 (en) * 2004-07-22 2010-10-15 Ucb Pharma Sa INDOLONE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022317A1 (en) * 1979-06-12 1981-01-14 Fujisawa Pharmaceutical Co., Ltd. 2-Oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives
US4624963A (en) * 1984-04-11 1986-11-25 Hoechst Aktiengesellschaft Use of oxindole compounds for the treatment of epilepsy
EP0445781A1 (en) * 1990-03-08 1991-09-11 Sterling Winthrop Inc. 3-Arylcarbonyl-1-aminoalkyl-1H-indole containing antiglaucoma compositions
WO1994029272A1 (en) * 1993-06-16 1994-12-22 Astra Aktiebolag 1-substituted isatin and oxindole derivatives as inhibitors of acetylcholinesterase
WO1998001428A1 (en) * 1996-07-08 1998-01-15 Du Pont Pharmaceuticals Company AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN
JPH1095766A (en) * 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd Acetamide derivative and its use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BELL, M. ET AL., J.MED.CHEM., vol. 34, no. 3, 1991, pages 1099 - 1110 *
CHEMICAL PATENTS INDEX, DOCUMENTATION ABSTRACTS JOURNAL Section Ch Week 9627, Derwent World Patents Index; Class B02, AN 96-266522, XP002241135 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002241130, Database accession no. BRN:6400176 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002241131, Database accession no. BRN:4296865 *
HOTZEL C ET AL: "Design, synthesis, DNA-binding and cytotoxicity evaluation of new potential combilexines", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 37, no. 5, May 2002 (2002-05-01), pages 367 - 378, XP004372953, ISSN: 0223-5234 *
NILSSON, I. ET AL., ACTA CHEM. SCAND. SER. B, vol. 39, no. 7, 1985, pages 531 - 548 *
PATENT ABSTRACTS OF JAPAN vol. 0133, no. 08 (C - 617) 14 July 1989 (1989-07-14) *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964593B2 (en) 2003-03-31 2011-06-21 Ucb Pharma, S.A. Indolone-acetamide derivatives, processes for preparing them and their uses
US7645887B2 (en) 2003-03-31 2010-01-12 Ucb Pharma, S.A. Indolone-acetamide derivatives, processes for preparing them and their uses
WO2005080334A1 (en) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
US7632856B2 (en) 2004-07-22 2009-12-15 Ucb Pharma, S.A. Indolone derivatives, processes for preparing them and their uses
WO2006008067A1 (en) * 2004-07-22 2006-01-26 Ucb, S.A. Indolone derivatives, processes for preparing them and their uses
KR101213345B1 (en) 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 Composition containing anti-dementia drug
WO2006128693A3 (en) * 2005-06-01 2007-04-19 Ucb Pharma Sa 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
US8178533B2 (en) 2005-06-01 2012-05-15 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
US8586623B2 (en) 2005-06-01 2013-11-19 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
US8518943B2 (en) 2005-06-01 2013-08-27 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
JP2008542323A (en) * 2005-06-01 2008-11-27 ユセベ ファルマ ソシエテ アノニム 2-Oxo-1-pyrrolidine derivatives, process for producing the same and use thereof
EP1931348A2 (en) * 2005-08-16 2008-06-18 ChemoCentryx Inc Monocyclic and bicyclic compounds and methods of use
EP1931348A4 (en) * 2005-08-16 2009-08-12 Chemocentryx Inc Monocyclic and bicyclic compounds and methods of use
JP2009504754A (en) * 2005-08-16 2009-02-05 ケモセントリックス インコーポレーティッド Monocyclic and bicyclic compounds and usage
US7868181B2 (en) 2006-02-07 2011-01-11 Astrazeneca Ab Compounds
WO2008132142A3 (en) * 2007-04-27 2009-01-15 Ucb Pharma Sa New heterocyclic derivatives useful for the treatment of cns disorders
WO2008132139A3 (en) * 2007-04-27 2008-12-31 Ucb Pharma Sa New heterocyclic derivatives useful for the treatment of cns disorders
WO2008132139A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
WO2008132142A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
EP3260118A1 (en) 2008-10-16 2017-12-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US8604075B2 (en) 2008-10-16 2013-12-10 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3827830A1 (en) 2014-01-21 2021-06-02 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN107540597A (en) * 2017-09-22 2018-01-05 苏州大学 The preparation method of the ketone derivatives of N dimethylacetamide bases indoles 2
WO2019232083A1 (en) * 2018-05-29 2019-12-05 New York University Compounds and methods for treating bacterial infections
KR102669101B1 (en) 2021-08-10 2024-05-27 충북대학교 산학협력단 A novel oxoindoline-based acetohydrazide and an anticancer composition comprising the same as an active ingredient
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Also Published As

Publication number Publication date
KR20050119186A (en) 2005-12-20
NO20055026D0 (en) 2005-10-28
CN1768036A (en) 2006-05-03
CN100364973C (en) 2008-01-30
US7645887B2 (en) 2010-01-12
ES2353461T3 (en) 2011-03-02
US20070043038A1 (en) 2007-02-22
EP1620399B1 (en) 2010-09-22
RU2005131317A (en) 2006-02-27
NO20055026L (en) 2005-12-22
HK1089768A1 (en) 2006-12-08
JP2006522041A (en) 2006-09-28
DE602004029245D1 (en) 2010-11-04
TW200508197A (en) 2005-03-01
ATE482193T1 (en) 2010-10-15
MXPA05009089A (en) 2005-11-17
EP1620399A1 (en) 2006-02-01
AU2004226288A1 (en) 2004-10-14
AR043959A1 (en) 2005-08-17
BRPI0408863A (en) 2006-04-11
US20100069375A1 (en) 2010-03-18
ZA200507231B (en) 2006-11-29
US7964593B2 (en) 2011-06-21
CA2520568A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
US7964593B2 (en) Indolone-acetamide derivatives, processes for preparing them and their uses
EP1452524B1 (en) "2-oxo-1-pyrrolidine derivative and its pharmaceutical uses"
US7763644B2 (en) Imidazole derivatives, processes for preparing them and their uses
KR100190672B1 (en) Glycinamide derivatives, processes for their preparation and medicines containing them
JP2010516697A (en) D-amino acid oxidase inhibitor
JPH05505599A (en) Therapeutically useful heterocyclic indole compounds
US20230295106A1 (en) Ergoline-like compounds for promoting neural plasticity
US20090018148A1 (en) Xanthine Derivatives, Processes For Preparing Them And Their Uses
AU2001252144A1 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
CA2882826A1 (en) Pro-neurogenic compounds
CA2715282A1 (en) Indole compounds and methods of use thereof
US7087596B2 (en) 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders
US8957218B2 (en) 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
RU2042680C1 (en) 1-[pyrido(3,4-b)-1,4-oxazinyl-4-yl]-1h-indoles, method of their synthesis, composition on their basis and derivative of n-(4-pyridinyl)-1h-indole-1-amine
CN101977907A (en) Pyrrolidinyl derivatives and uses thereof
KR100433609B1 (en) Tricyclic benzo[e]isoindoles and benzo[h]isoquinolines
US8293775B2 (en) Benzoxazolone derivatives, processes for preparing them and their uses
US4578397A (en) Indeno(1,2-b)pyrrole derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009089

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 170691

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200507231

Country of ref document: ZA

Ref document number: 4027/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004720863

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2005-501651

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 542431

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2520568

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004226288

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006504696

Country of ref document: JP

Ref document number: 20048087283

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020057018789

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005131317

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004226288

Country of ref document: AU

Date of ref document: 20040316

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004226288

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020057018789

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004720863

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408863

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2007043038

Country of ref document: US

Ref document number: 10550667

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10550667

Country of ref document: US